Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

PBPurple Biotech Ltd.

$1.4

+0.03 (+2.19%)

D 32Pipeline Score Fair Value Pharma · Clinical
Market Cap
6.40 M
EPS
-32.52
P/E Ratio
-
Value Trade
24.20 K
-28 %
Week
-38.98 %
1 Month
-47.06 %
3 Month
-60.76 %
6 Month
-99.67 %
5 Year
-99.96 %
All Time
Cash Data

  • Cash Position

    12.35 K

  • Monthly Burn

    12.35 K

  • Runway

    12,345 mo

Overview
Volume
17.18 K
52 Week Range
2.52 - 29
% held by Insiders
0.1 %
% held by Institutions
4.67 %
Enterprise Value
102.57 K
Total Shares
929.24 K
Short %
1.13 %
Float Shares
928.30 K
Company Description
Employees:10
https://www.purple-biotech.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data

Catalyst Timeline

Dated clinical, regulatory & corporate events for Purple Biotech Ltd.

515Total events
7Upcoming
149Tier-1 (high impact)
2015 – 2027Coverage

Upcoming catalysts 2

TBD
T2Trial Initiation
Subscribe to view catalyst details
IM1240
TBD
T2First Patient Dosed
Subscribe to view catalyst details
IM1240

Event history 2

TBD
◆Trial InitiationIM1240Trial
Subscribe to view catalyst details
TBD
▲Enrollment CompleteIM1240Trial
Subscribe to view catalyst details
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2024-12-31
CM24
Phase 2 data readout
Phase 2
—
–
–
–
2024-12-31
CM24
Phase 2 data readout
Phase 2
—
–
–
–
2024-12-31
CM24
Phase 2 data readout
Phase 2
—
–
–
–
Unlock 1 more historical catalysts
Drug Pipeline Intelligence
D32
Pipeline Score
$6M
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
0.9x
rNPV / MCap
Top 42%
Micro Cap
(rank 531 of 913)
Percentile Rank
Purple Biotech Ltd. faces pipeline headwinds (32/100), with $443M risk-adjusted pipeline value, led by NT219 in Head and Neck Cancer (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
NT219
Small molecule		Solid Tumor, AdultPhase 1NCT0447447010% $193M COMPLETED 52 - -May 8, 2024 -Sep 19, 2024
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
CM24
pancreatic ductal adenocarcinoma (PDAC)
Phase 2
2025-08-06

Positive Phase 2 data from CM24 study in biomarker-enriched pancreatic ductal adenocarcinoma (PDAC) reported at AACR 2025

Read More

Purple Biotech Reports Second Quarter 2025 Financial Results Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform's masked CD3, NKG

Read More
CM24
pancreatic ductal adenocarcinoma (PDAC)
Phase 2
2025-08-06

Positive Phase 2 data from CM24 study in biomarker-enriched pancreatic ductal adenocarcinoma (PDAC) reported at AACR 2025

Read More

Purple Biotech Reports Second Quarter 2025 Financial Results Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform's masked CD3, NKG

Read More
CM24
pancreatic ductal adenocarcinoma (PDAC)
Phase 2
2025-08-06

Positive Phase 2 data from CM24 study in biomarker-enriched pancreatic ductal adenocarcinoma (PDAC) reported at AACR 2025

Read More

Purple Biotech Reports Second Quarter 2025 Financial Results Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform's masked CD3, NKG

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in PPBT
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
PPBT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-11-20 0.00 0 - - - - - -
2026-11-20 0.00 0 - - - - - -
2026-11-20 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-PPBT
Jun 11, 2026
PPBTPhases
▼ -48%on this news

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Purple Biotech presented promising preclinical data for IM1240 at EACR 2026, highlighting its anti-tumor efficacy in chemotherapy-resistant cancers. The study demonstrated improved pharmacokinetics and a favorable safety profile compared to non-capped variants. IM1240's mechanism involves inducing immune cell structures that enhance anti-tumor responses, supporting its advancement towards clinical trials in 2027.

Read more →
-PPBT
May 15, 2026
PPBTGeneral
▲ +6.8%on this news· ran to -19% by day 3

Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights

Purple Biotech reported its Q1 2026 financial results, highlighting the promising anti-tumor activity of its tri-specific antibody IM1240. The company established a Scientific Advisory Board and expanded its collaboration with Converge Bio to enhance antibody development using AI. Despite increased operating expenses, the company maintains a solid cash position expected to last into 2027.

Read more →
-PPBT
Apr 27, 2026
PPBTPhases

Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240 Data, generated in the lab of Dr. Amir Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, demonstrated that

Purple Biotech has announced promising preclinical data regarding its lead tri-specific antibody, IM1240, from the CAPTN-3 platform. This data, generated in collaboration with Dr. Amir Horowitz at the Icahn School of Medicine at Mount Sinai, showed that all seven tested patient-derived tumor samples responded positively to IM1240 treatment. Notably, the treatment enhanced anti-tumor activity and induced favorable immune responses in various cancer types, including resistant cases. The results suggest IM1240's potential as a significant therapeutic option for patients with difficult-to-treat cancers.

Read more →
-PPBT
Apr 23, 2026
PPBTGeneral
▼ -8.1%on this newsshared move

Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform Scientific Advisory Board (SAB) includes experts in the development and approved T-cell engager therap

Purple Biotech has announced the formation of a Scientific Advisory Board (SAB) to support the development of its CAPTN-3 tri-specific antibody platform for immunotherapy. The SAB includes renowned experts in the fields of T cell and NK cell therapies, aimed at enhancing the efficacy and safety of anti-cancer treatments. This new advisory team will provide strategic guidance as Purple Biotech progresses toward clinical development, leveraging a unique approach in immunotherapy that targets tumor-associated antigens while engaging immune cells. The CAPTN-3 platform is designed to confine immune activation to the tumor microenvironment, which could improve therapeutic outcomes.

Read more →
-PPBT
Mar 25, 2026
PPBTGeneral

Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform Collaboration leverages Converge Bio's proprietary generative AI to design and o

Purple Biotech has announced a collaboration with Converge Bio to enhance the development of its next-generation tri-specific antibody platform through the use of advanced generative AI. This partnership aims to leverage AI capabilities to improve the design and optimization of antibodies specifically for oncology applications. The collaboration seeks to accelerate discovery timelines, enhance the quality of drug candidates, and expand Purple Biotech's pipeline with high-quality therapeutics. The integration of AI technologies marks a significant step in Purple Biotech's strategy to lead in multi-specific antibody therapies.

Read more →
-PPBT
Mar 19, 2026
PPBTGeneral

CORPORATE PRESENTATION March 2026 Advancing the next Generation of Immuno - oncology NASDAQ/TASE : PPBT 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking an

PPBT is advancing its lead program IM1240, a tri-specific antibody designed to target solid tumors, with clinical trials planned to begin in 2027. The CAPTN - 3 platform showcases improved safety and efficacy metrics, potentially addressing challenges faced by current T-cell engagers. The company is optimistic about ongoing partnerships related to its Phase 2 programs, CM24 and NT219, which show positive clinical data. Financially, PPBT is secure through key milestones, ensuring operations continue into 2027.

Read more →
-PPBT
Mar 17, 2026
PPBTGeneral

Purple Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

Purple Biotech Ltd. has successfully regained compliance with Nasdaq's minimum bid price requirement, confirming it can continue listing on the platform. The company achieved the minimum closing bid price for its American Depositary Shares (ADSs) of $1.00 or more over 10 consecutive business days. Purple Biotech is focused on its next-generation immunotherapy platform, particularly advancing its lead candidate IM1240 and further developing candidates IM1305 and CM24, which have shown promise in clinical trials.

Read more →
-PPBT
Mar 13, 2026
PPBTGeneral
▲ +6.8%on this newsshared move

Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results Prioritized development of first tri-specific antibody from the CAPTN-3 platform, IM1240, targeting 5T4 tumor-associated antigen, and second tri-

Purple Biotech reported its fourth quarter and full year 2025 financial results, emphasizing the prioritization of the CAPTN-3 platform's tri-specific antibodies IM1240 and IM1305. The company achieved important preclinical milestones, including positive data presented at the ESMO Immuno-Oncology Congress 2025. However, it also faced a substantial impairment loss of $20.5 million due to the reassessment of other developmental assets, impacting its overall financial performance for the year.

Read more →
-PPBT
Feb 25, 2026
PPBTGeneral

Purple Biotech Announces Plan to Implement ADS Ratio Change ADS Will Begin Trading Reflecting the Ratio Change on

Purple Biotech Ltd. has announced a change to its American Depositary Shares (ADS) ratio, effective from March 2, 2026. The ratio will change from one ADS representing 200 ordinary shares to one ADS representing 2,000 ordinary shares. This adjustment aims to help the company meet the $1.00 minimum bid price requirement for continued Nasdaq listing. While the change may enhance the liquidity of ADS trading, the company has cautioned that there is no assurance regarding the post-change trading price.

Read more →
-PPBT
Jan 13, 2026
PPBTGeneral

CORPORATE PRESENTATION January 2026 Advancing the next Generation of Immuno - oncology NASDAQ/TASE : PPBT Certain statements in this presentation that are forward - looking and not statements of historical fact are forwa

The corporate presentation details PPBT's progress in advancing the CAPTN-3 platform for immuno-oncology. Noteworthy is the impending Phase 1 initiation of the tri-specific antibody IM1240 in H2 2026, and positive data from two Phase 2 clinical programs that present partnership opportunities. The presentation also emphasizes the platform's enhanced safety and efficacy for targeting solid tumors. However, challenges related to drug development timelines, regulatory approvals, and market uncertainties were highlighted.

Read more →
-PPBT
Jan 7, 2026
PPBTPhases

Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240 IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fo

Purple Biotech has announced the successful completion of a toxicology study for its tri-specific antibody, IM1240, showing an expanded therapeutic window. The study indicated that IM1240 can be dosed up to 300-fold higher than a non-capped comparator while demonstrating improved safety, particularly through reduced immune-related toxicity. The company plans to advance IM1240 toward first-in-human clinical trials, with regulatory submission expected in the second half of 2026. These findings suggest a promising future for IM1240 in immunotherapy applications against solid tumors.

Read more →
-PPBT
Dec 11, 2025
PPBTPhases

Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025 Data demonstrates the significant and sust

Purple Biotech has reported promising preclinical results from its CAPTN-3 tri-specific antibody platform at the ESMO Immuno-Oncology Congress 2025. The data showcases two antibodies, IM1240 and IM1305, demonstrating significant anti-tumor activity across various solid tumors, including cases resistant to PD1 therapy. This platform unites multiple immunological mechanisms, indicating its potential broad applicability in cancer treatment. The findings highlight Purple Biotech's ongoing development efforts as it prepares for key milestones in 2026.

Read more →
-PPBT
Nov 19, 2025
PPBTGeneral

NASDAQ/TASE: PPBT November 2025 CORPORATE PRESENTATION 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward -

Purple Biotech presented a corporate overview highlighting its pipeline of oncology products, including two promising candidates, CM24 and NT219. CM24 has demonstrated positive results in early-stage clinical trials aimed at personalized immunotherapy for cancer, while NT219 targets tumor resistance mechanisms. The company is strategically positioned to advance its first-in-class dual conditionally-activated therapies, with a significant cash balance providing development runway through early 2027. The potential impacts of current regulatory environments and market dynamics were also outlined as critical factors for future performance.

Read more →
-PPBT
Nov 14, 2025
PPBTGeneral

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the fi

Purple Biotech reported its financial results for Q3 2025 and outlined key updates in its business operations. The company initiated the development of a second CAPTN-3 tri-specific antibody targeting TROP2 and achieved a manufacturing milestone for IM1240. Despite a cash position of $10.5 million that extends its runway into early 2027, Purple Biotech recorded a net loss of $1.3 million, an increase from the previous year's loss. The company continues to focus on toxicology studies and advancing its CAPTN-3 technology platform moving forward.

Read more →
-PPBT
Oct 28, 2025
PPBTGeneral

NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of Shareholders (the " Meeting ") of Purple Biotech Ltd. (the " Company ") will be held on Monday

Purple Biotech Ltd. has announced an Extraordinary General Meeting of Shareholders scheduled for December 15, 2025. The primary agenda is to approve the grant of equity-based awards to CEO Mr. Gil Efron and the board of directors. All shareholders of record as of November 3, 2025, are entitled to vote, either in person or via proxy. Detailed voting instructions have been provided for various types of shareholders to ensure participation.

Read more →
-PPBT
Oct 16, 2025
PPBTGeneral

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification REHOVOT, Israel, October 20 , 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-sta

Purple Biotech Ltd. announced that it received a notification from Nasdaq indicating it is not in compliance with the minimum bid price requirement. The company's American Depositary Shares have been below $1.00 for 30 consecutive trading days. Purple Biotech has a 180-day period to regain compliance, failing which it may face delisting. The notification does not immediately affect its listing on the Tel Aviv Stock Exchange.

Read more →
-PPBT
Sep 10, 2025
PPBTGeneral
▼ -5.3%on this news

NASDAQ/TASE: PPBT September 2025 CORPORATE PRESENTATION 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward

Purple Biotech is advancing its pipeline of first-in-class oncology therapies, including NM219 and CM24, and reported promising Phase 2 results. The company has emphasized the potential risks associated with drug development, including regulatory hurdles and market competition. With a strong cash balance providing operational runway until mid-2027, Purple Biotech is positioning itself for future growth in the oncology sector. However, ongoing challenges, such as the lengthy drug approval process and potential legal issues, are acknowledged.

Read more →
-PPBT
Sep 10, 2025
PPBTPhases
▼ -5.3%on this news

Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance A Phase 2 study for NT219 in combination with immunotherapy is

Purple Biotech has received an intention to grant a European Patent for its combination therapy using NT219. This patent aims to protect NT219's use with several leading immunotherapies and MEK inhibitors, potentially enhancing effectiveness against resistant cancers. A Phase 2 clinical study is currently underway, focusing on the use of NT219 in combination with pembrolizumab or cetuximab for treating squamous cell carcinoma of the head and neck. The company aims to improve treatment outcomes for patients with resistant tumors.

Read more →
-PPBT
Sep 4, 2025
PPBTGeneral
▼ -45.1%on this news· ran to -58% by day 3

Purple Biotech Announces Pricing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Purple Biotech Ltd. has announced the pricing of a public offering aimed at raising up to $18 million, consisting of approximately 6 million upfront and a potential additional $12 million from short-term warrants. The offering involves American Depositary Shares (ADSs) and associated warrants priced at $1.00 each. The company plans to utilize the proceeds for the development of its oncology therapeutic candidates and for general operational purposes, with the closing expected shortly.

Read more →
-PPBT
Sep 4, 2025
PPBTPhases
▼ -45.1%on this news· ran to -58% by day 3

Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai Mt. Sinai Principal Investigator, Dr. Amir Horowitz

Purple Biotech announced new data supporting the design of its CAPTN-3 tri-specific antibody IM1240, developed in collaboration with the Icahn School of Medicine at Mount Sinai. This data reveals that IM1240 induced tumor cell death in treatment-resistant head and neck biopsies, showing synergistic effects between its NK and T cell engager arms. The findings suggest a promising mechanism of action that may lead to the incorporation of IM1240 in upcoming clinical trials, with an IND submission projected for 2026.

Read more →
-PPBT
Sep 3, 2025
PPBTPhases

Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2 Encouraging in-vivo results demonstrate sustained tumor regression with the CD3xTROP2xNKG2A antibody First CAPTN-3 tri-s

Purple Biotech announced the advancement of IM1305, a novel tri-specific antibody targeting TROP2, which has shown promising in-vivo results in tumor regression. This antibody is developed from the CAPTN-3 platform, designed to activate both innate and adaptive immune systems. The preclinical studies indicate significant efficacy in various cancer types at low doses. The company aims to leverage its technological advancements from previous developments as it expands its portfolio.

Read more →
-PPBT
Aug 6, 2025
PPBTPhases

Purple Biotech Reports Second Quarter 2025 Financial Results Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform's masked CD3, NKG

Purple Biotech reported its financial results for Q2 2025, highlighting advancements in their CAPTN-3 tri-specific antibody platform, which is progressing towards first-in-human clinical trials. The company has achieved positive results in the Phase 2 CM24 study for pancreatic cancer and initiated a Phase 2 study of NT219 in head and neck cancer. Financially, Purple Biotech showed a decrease in operating loss and expenses from the previous year, but a reduction in net finance income suggests ongoing financial challenges. The company is actively seeking partnerships to support its research and development efforts.

Read more →
-PPBT
Jul 23, 2025
PPBTGeneral

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Purple Biotech Ltd. has released a letter to shareholders detailing scientific progress and clinical milestones achieved in the first half of 2025. CEO Gil Efron highlighted improvements in core programs, including advancements in therapies targeting tumor immune evasion. The company has also maintained a disciplined financial strategy, projecting a runway into mid-2026. However, they noted the need for additional funding to continue growth amid a challenging market environment.

Read more →
-PPBT
Jul 10, 2025
PPBTGeneral

NASDAQ/TASE: PPBT July 2025 CORPORATE PRESENTATION 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - loo

Purple Biotech presented its corporate outlook, emphasizing its development of innovative cancer therapies including CM24 and NT219. The company highlighted successful Phase 2 clinical trial results, particularly in treating pancreatic cancer, and discussed ongoing investment opportunities. However, they acknowledged significant challenges related to regulatory approvals, competition, and potential litigation risks. The presentation reflects the company's strategic approach to addressing high unmet medical needs in oncology.

Read more →
-PPBT
Jun 23, 2025
PPBTConferences/Events

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Purple Biotech has presented new preclinical data on its CAPTN-3 tri-specific antibody platform at the EACR 2025 Annual Congress. This platform aims to overcome tumor immune evasion and enhance immune responses against solid tumors by engaging both T cells and natural killer cells. The poster presentation highlighted the unique action of the anti-NKG2A arm in conjunction with the anti-CD3 arm, which could significantly improve cytotoxic activity against cancer cells. The innovative design suggests a promising therapeutic approach with localized action in the tumor microenvironment.

Read more →
-PPBT
Jun 17, 2025
PPBTPhases

Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in co

Purple Biotech has announced the initiation of a Phase 2 clinical study for NT219, targeting recurrent and/or metastatic squamous cell carcinoma of the head and neck. The study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus, will evaluate NT219 in combination with standard treatments like pembrolizumab and cetuximab. This advancement follows encouraging results from a prior Phase 1 study, which demonstrated NT219's safety and anti-tumor activity. The Phase 2 study aims to deliver on significant milestones for the company this year.

Read more →
-PPBT
May 21, 2025
PPBTPhases

Purple Biotech Reports First Quarter 2025 Financial Results Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Secon

Purple Biotech has shared its financial results for Q1 2025, highlighting the presentation of final CM24 Phase 2 data and progress on NT219. The company reported a reduced operating loss of $1.4 million, showing improved expense management. Positive data presentations at the AACR Annual Meeting strengthen the patient selection strategy for CM24 and initiate a Phase 2 study of NT219. The company's financial position is stable, with cash reserves expected to last into mid-2026.

Read more →
-PPBT
May 12, 2025
PPBTGeneral

Purple Biotech Appoints Shai Lankry as Chief Financial Officer U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational

Purple Biotech has appointed Shai Lankry as Chief Financial Officer, who brings over 20 years of experience in the biotech and healthcare sectors. Lankry's background includes leading U.S. IPOs and M&A transactions, enhancing the company's financial capabilities at a critical time as it advances its clinical pipeline. His experience is expected to support Purple Biotech's growth and clinical development programs, particularly in novel therapies aimed at overcoming tumor immune evasion and drug resistance.

Read more →
-PPBT
May 6, 2025
PPBTGeneral
▼ -8.9%on this news

NASDAQ/TASE: PPBT May 2025 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward -

Purple Biotech (NASDAQ/TASE: PPBT) has outlined their corporate presentation for May 2025, detailing forward-looking statements about their pipeline and financial position. The company has a cash balance of $8.2 million and aims to advance two first-in-class oncology therapies, CM24 and NT219. However, they acknowledge the risks inherent in product development and regulatory approval processes, along with competition within the pharmaceutical landscape.

Read more →
-PPBT
Apr 30, 2025
PPBTPhases
▼ -5.2%on this news

Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups Statistically significant

Purple Biotech announced positive findings from its Phase 2 study of CM24 in pancreatic cancer patients at the AACR 2025 Annual Meeting. Results indicate a significant improvement in overall survival and progression-free survival among patients with specific biomarker expressions. The study, which involved a combination of CM24, nivolumab, and chemotherapy, reported a 90% reduction in the risk of death compared to the control group. The company plans to further explore these findings through a Phase 2b study to refine patient selection based on biomarker identification.

Read more →
-PPBT
Apr 28, 2025
PPBTConferences/Events

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers Activated b -catenin or loss of its negative regulator adenomatous polyposis coli (APC) is a potential biomarker for NT219 in th

Purple Biotech announced promising results for NT219 at the AACR 2025 conference, showcasing its potential as a dual inhibitor for colorectal and head and neck cancers. Key findings indicated that activated forms of STAT3 and IGF1R may serve as biomarkers for NT219 therapy response. These results support further study design and patient selection strategies in ongoing clinical trials for R/M HNSCC. The company continues to advance NT219 in Phase 2 studies in collaboration with the University of Colorado.

Read more →
-PPBT
Apr 16, 2025
PPBTPhases

Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer Findings show combination therapy of NT219 and 5-flourouracil (5-F

Purple Biotech has announced the publication of a study in the Neuro Oncology journal, demonstrating NT219's potential to suppress brain metastasis in colorectal cancer when combined with 5-fluorouracil (5-FU). The study highlights IRS2 as a critical target, revealing that this combination not only inhibits metastasis but also extends survival in preclinical models. CEOC Gil Efron indicated plans to advance NT219 into a Phase 2 study for other cancer indications, underscoring the drug's promising therapeutic potential.

Read more →
-PPBT
Apr 1, 2025
PPBTConferences/Events

Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on

Purple Biotech Ltd. (PPBT) announced that CEO Gil Efron will participate in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025. The panel will focus on innovative approaches to radiotherapy and targeted therapies. Purple Biotech is developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance, with notable advancements in their oncology pipeline. Noteworthy therapeutic candidates include CM24, NT219, and CAPTN-3, showcasing the company's commitment to cutting-edge cancer treatment solutions.

Read more →
-PPBT
Mar 28, 2025
PPBTConferences/Events

Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting

Purple Biotech Ltd. announced that three research posters will be presented at the 2025 American Association for Cancer Research Meeting. These presentations will highlight the clinical research regarding their therapies CM24 for pancreatic cancer and NT219 for colorectal and head and neck cancers. The meeting is set to take place from April 25 to April 30 in Chicago, showcasing new advancements in cancer treatment.

Read more →
-PPBT
Mar 18, 2025
PPBTGeneral

NASDAQ/TASE: PPBT March 2025 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward

Purple Biotech (NASDAQ/TASE: PPBT) has released its corporate presentation outlining forward-looking statements related to its drug development pipeline, focusing on two first-in-class oncology therapies, CM24 and NT219. The company emphasizes the risks associated with drug development, regulatory approvals, and market competition while highlighting cash reserves that provide operational stability into mid-2026. The presentation notes the clinical benefits observed for its lead drug candidates and plans for upcoming clinical trials.

Read more →
-PPBT
Mar 10, 2025
PPBTPhases

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results Completed successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkers CM2

Purple Biotech Ltd. announced its fourth quarter and full-year 2024 financial results, highlighting the successful completion of clinical trials for its oncology assets CM24 and NT219. CM24 showed promising efficacy in a pancreatic cancer trial, while NT219 is set to enter a Phase 2 study in head and neck cancer. The company also reported reduced operating and net losses compared to the previous year, reflecting a positive trend in managing expenses. Additionally, ongoing research collaborations aim to enhance the understanding and effectiveness of its therapy platforms.

Read more →
-PPBT
Mar 5, 2025
PPBTPhases

Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently enterin

Purple Biotech Ltd. has been granted a new U.S. patent for its drug NT219, which is designed to combat tumor resistance when used with EGFR antibody therapies like cetuximab. This patent enhances the company's intellectual property protection across major global markets—including the U.S., Europe, China, and Japan. NT219 is currently advancing into a Phase 2 clinical study for patients with recurrent and/or metastatic head and neck cancer, which is projected to see substantial market growth. The CEO of Purple Biotech expressed confidence in the patent's contribution to potential future commercialization.

Read more →
-PPBT
Feb 28, 2025
PPBTConferences/Events

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the " Meeting ") of Purple Biotech Ltd. (the " Company ") will be held on Tuesday

Purple Biotech Ltd. is scheduled to hold its Annual General Meeting of Shareholders on April 15, 2025. The meeting will take place at the company's executive offices in Rehovot, Israel, and aims to review financial statements from 2024. Shareholders of record by March 6, 2025, are invited to participate either in person or via proxy. Voting instructions and other details regarding shareholder participation have been outlined.

Read more →
-PPBT
Feb 18, 2025
PPBTPhases

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck c

Purple Biotech has announced the advancement of its novel agent NT219 into a Phase 2 trial targeting recurrent and metastatic squamous cell carcinoma of the head and neck. The study will evaluate NT219 in combination with the established therapies pembrolizumab and cetuximab to assess efficacy and safety against tumor resistance. Conducted in collaboration with the University of Colorado Anschutz Medical Campus, the trial's design aims to explore biomarkers identified in earlier studies. This development reflects Purple Biotech's commitment to addressing significant treatment gaps in head and neck cancer therapies.

Read more →
-PPBT
Feb 3, 2025
PPBTGeneral

Purpl e Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform Collaboration to explore the immunoregulation of NK and T cells within the tumo

Purple Biotech Ltd. has announced a research collaboration with the Icahn School of Medicine at Mount Sinai to enhance its CAPTN-3 tri-specific antibody platform. This partnership aims to explore the immunoregulation of NK and T cells within the tumor microenvironment, potentially leading to improved cancer therapies. Notably, the collaboration is expected to deepen the understanding of immune evasion mechanisms associated with tumors. Purple Biotech's involvement with Dr. Amir Horowitz, an expert in immunology, highlights the strategic advantage of this cooperation.

Read more →
-PPBT
Dec 6, 2024
PPBTGeneral
▲ +17.2%on this news

NASDAQ/TASE: PPBT December 2024 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forwa

Purple Biotech (NASDAQ/TASE: PPBT) detailed its corporate presentation in December 2024, focusing on forward-looking statements regarding its drug development pipeline. The company holds a cash balance of $6.3 million, with an additional $4.0 million raised recently, highlighting its financial stability to reach key clinical milestones. Two first-in-class oncology therapies, CM24 and NT219, are in various stages of clinical development, aimed at addressing significant unmet medical needs in cancer treatment. However, they acknowledge various risks associated with drug development, including regulatory challenges and market competition.

Read more →
-PPBT
Dec 5, 2024
PPBTGeneral
▼ -16.9%on this newsshared move

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech Ltd. has announced the successful closure of its registered direct offering, securing approximately $2.8 million from the sale of 472,668 American Depositary Shares at a price of $6.00 each. The funds raised will be allocated toward the development of the company's oncology therapeutic candidates and for general working capital. The offering follows a shelf registration statement previously filed with the SEC, and electronic copies of the final prospectus supplement can be accessed via the SEC's website.

Read more →
-PPBT
Dec 3, 2024
PPBTGeneral
▼ -21.8%on this news· ran to -44% by day 3shared move

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech Ltd. has announced a $2.8 million registered direct offering of American Depositary Shares aimed at funding its oncology therapies. The offering involves the sale of 472,668 ADSs at a price of $6.00 each, with the closing expected around December 4, 2024. Proceeds will be allocated toward developing their clinical-stage therapeutic candidates and general corporate purposes. This initiative follows the company's promising results in clinical studies, furthering its mission to innovate cancer treatments.

Read more →
-PPBT
Dec 2, 2024
PPBTPhases
▲ +150.4%on this newsshared move

Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and con

Purple Biotech has announced positive final results from its Phase 2 study of CM24, an experimental drug for second-line treatment of pancreatic cancer. The study showed significant improvement in overall survival and progression-free survival when CM24 was combined with nivolumab and standard chemotherapy. Notably, subgroup analyses revealed that patients with elevated serum CEACAM1 levels showed particularly promising outcomes. Given these findings, Purple Biotech is planning further clinical trials to expand the indication of CM24 for various CEACAM1-expressing tumors.

Read more →
-PPBT
Nov 15, 2024
PPBTPhases

Purple Biotech Reports Third Quarter 2024 Financial Results Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including

Purple Biotech reported third quarter 2024 financial results, highlighting significant advancements in their Phase 2 CM24 trial for pancreatic cancer, with topline data expected by year-end. New data revealed promising biomarker findings, indicating enhanced treatment potential through serum biomarkers. The company showcased financial improvements, including reduced operating losses and a cash runway extending to Q4 2025. However, some trial data faced limitations due to censoring issues which may impact analysis.

Read more →
-PPBT
Nov 4, 2024
PPBTPhases

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death Patients with serum CEACAM1 within a defined range prior to treatme

Purple Biotech has identified a potential new serum biomarker, CEACAM1, which may enhance patient selection for its oncology candidate CM24. In patients with metastatic pancreatic cancer, those exhibiting serum CEACAM1 levels within a specific range experienced greater overall and progression-free survival following treatment. CM24, a CEACAM1 inhibitor, is currently being assessed in a Phase 2 study, with results anticipated in late 2024. This discovery is expected to provide a significant advantage in treatment outcomes for cancer patients, particularly those with pancreatic cancer.

Read more →
-PPBT
Oct 25, 2024
PPBTConferences/Events
▼ -9.3%on this news· ran to -32% by day 1

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CAPTN-3 demonstrates sustai

Purple Biotech has announced promising new data for its tri-specific antibody platform, CAPTN-3, presented at the EORTC-NCI-AACR Symposium. The platform shows significant tumor regression in triple negative breast cancer and demonstrates a potentially enhanced safety profile for its lead candidate, IM1240. The technology enables simultaneous engagement of T cells and NK cells, suggesting a powerful mechanism for anti-tumor activity. The company aims to advance IM1240 into first-in-human clinical studies by 2026.

Read more →
-PPBT
Oct 10, 2024
PPBTConferences/Events

Purple Biotech to Present Data for its Tri-Specific Antibody Platform-CAPTN-3-at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CAPTN-3 is a conditionally activated tri-specific antibody platfo

Purple Biotech has announced its participation in the upcoming EORTC-NCI-AACR Symposium, where it will present data related to its innovative CAPTN-3 tri-specific antibody platform. This platform is designed to engage both T and NK cells to optimize anti-tumoral immune responses. Lead candidate IM1240 targets 5T4, an antigen correlated with poor clinical outcomes in various cancers. The presentation underscores the company’s progress in developing therapies aimed at overcoming tumor immune evasion.

Read more →
-PPBT
Oct 9, 2024
PPBTGeneral

NASDAQ/TASE: PPBT October 2024 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forwar

Purple Biotech (NASDAQ/TASE: PPBT) presented their October 2024 corporate presentation, highlighting their position and clinical pipeline in oncology. The company reports a cash balance of $7.3 million with additional funding secured, supporting ongoing development. CM24, a new multi-functional CEACAM1 inhibitor, shows promise in treating pancreatic cancer, accompanied by multiple data read-outs expected in the coming year. However, the lengthy drug development process and potential regulatory challenges pose significant risks to the company's future success.

Read more →
-PPBT
Sep 18, 2024
PPBTPhases

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24 High CEACAM1 and low PDL1 expression in tumors, as well as their combination ide

Purple Biotech has reported positive interim data from its Randomized Phase 2 study of CM24, a candidate targeting CEACAM1 in pancreatic cancer. Data presented at the AACR conference indicates that CM24, in combination with nivolumab and chemotherapy, may significantly decrease patient mortality risk. The company's findings emphasize the potential of high CEACAM1 expression and low PDL1 levels as beneficial biomarkers for treatment outcomes. Additional results are anticipated in late 2024, establishing further support for the therapy's effectiveness.

Read more →
-PPBT
Aug 19, 2024
PPBTGeneral

NASDAQ/TASE: PPBT August 2024 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward

Purple Biotech (PPBT) has outlined its corporate presentation for August 2024, highlighting its ongoing development of first-in-class oncology therapies. The company reports a strong cash balance of $7.3 million, with additional fundraising and multiple data read-outs expected throughout the year. However, the presentation emphasizes the inherent risks in drug development, which include lengthy timelines, regulatory uncertainties, and complexities surrounding market reception. Key therapeutic candidates include CM24 and NT219, targeting various cancer indications.

Read more →
-PPBT
Aug 16, 2024
PPBTPhases

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights Positive randomized Phase 2 CM24 pancreatic cancer study interim data presented at the American Society of Clinical Oncology ( ASCO) 20

Purple Biotech has reported positive interim results from its randomized Phase 2 CM24 pancreatic cancer study, showing significant improvements in various efficacy endpoints. The company's cash runway has been extended to Q3 2025, allowing them more time to achieve their developmental goals. Additionally, there are plans to expand the CM24 clinical program to include biomarker-driven studies, targeting new indications based on promising data. The findings were highlighted during the recent ASCO 2024 Annual Meeting.

Read more →
-PPBT
Jul 25, 2024
PPBTGeneral

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Purple Biotech Ltd. has received a 180-day extension from Nasdaq to meet the minimum bid price rule necessary for continued listing. The company has until January 21, 2025, to ensure that its American Depositary Shares (ADSs) maintain a closing bid price of at least $1.00 for ten consecutive business days. Although the extension allows continued trading on Nasdaq, failure to meet compliance could jeopardize its listing status. Purple Biotech continues to develop its oncology pipeline, which includes several first-in-class therapies.

Read more →
-PPBT
Jul 19, 2024
PPBTGeneral

NASDAQ/TASE: PPBT July 2024 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward -

Purple Biotech (NASDAQ/TASE: PPBT) presented its corporate outlook for July 2024, outlining forward-looking statements and strategic objectives. The company highlighted a strong cash position and anticipates multiple data read-outs in 2024 for its first-in-class oncology therapies. However, it acknowledged significant risks inherent in the drug development process, including regulatory hurdles and market competition. The presentation emphasized the importance of cautious optimism in navigating these uncertainties.

Read more →
-PPBT
Jul 2, 2024
PPBTGeneral

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Ltd. announced the successful closing of the exercise of warrants, raising approximately $2 million in gross proceeds. The warrants involved the purchase of 5,633,509 American Depositary Shares at a significantly reduced price. The funds will be utilized to further the development of its oncology therapeutic candidates and for general corporate purposes. Additionally, the company issued new Series A-1 and A-2 warrants to enhance future funding options.

Read more →
-PPBT
Jul 1, 2024
PPBTGeneral
▼ -11.8%on this newsshared move

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech has announced the exercise of warrants resulting in gross proceeds of approximately $2 million. The exercise involves 5,633,509 American Depositary Shares at a reduced price of $0.36 each. The funds will be directed towards developing its oncology therapies and for general corporate needs. Additionally, the company is preparing to issue new unregistered warrants as part of this financing activity, with the offering expected to close shortly after the announcement.

Read more →
-PPBT
Jun 27, 2024
PPBTPhases
▼ -8.8%on this news· ran to -23% by day 3shared move

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit New data suggests that base

Purple Biotech has announced additional positive interim results from its Phase 2 study of CM24, in combination with nivolumab and standard chemotherapy, for metastatic pancreatic ductal adenocarcinoma. The results indicate a 26% reduction in death risk and improvements in overall survival and progression-free survival metrics. A potential predictive biomarker, serum MPO, has been identified, which may signal better clinical outcomes when using this treatment combination. Purple Biotech plans to provide further updates during a KOL event and report more clinical study data later in 2024.

Read more →
-PPBT
Jun 26, 2024
PPBTGeneral

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the " Meeting ") of Purple Biotech Ltd. (the " Company ") will be held on Thursday

Purple Biotech Ltd. is scheduled to hold its Annual General Meeting of Shareholders on August 8, 2024. The agenda includes the re-election of Mr. Issac Israel and Ms. Suzana Nahum-Zilberberg as directors for a three-year term. Management will also present the consolidated financial statements for the year ending December 31, 2023. Only shareholders and ADS holders who are registered as of the Record Date, July 2, 2024, will be eligible to attend and vote.

Read more →
-PPBT
Jun 4, 2024
PPBTGeneral
▼ -16.2%on this news

NASDAQ/TASE: PPBT June 2024 CORPORATE PRESENTATION Forward - looking Statements and Safe Harbor | 2 Certain statements in this presentation that are forward - looking and not statements of historical fact are forward -

Purple Biotech (NASDAQ/TASE: PPBT) provided a corporate presentation highlighting its forward-looking statements regarding product development and potential market performance. The company emphasizes its commitment to oncology therapies, particularly its lead drug candidates for treating cancers with significant unmet needs. They are aiming for multiple data readouts in 2024, indicating a focused approach to advancing their clinical pipeline while acknowledging the inherent risks in drug development and regulatory processes.

Read more →
-PPBT
Jun 1, 2024
PPBTPhases
▼ -8.4%on this news· ran to -24% by day 3shared move

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer 26% reduction in risk of death (

Purple Biotech has announced encouraging interim results from its randomized Phase 2 trial of CM24 in combination with nivolumab and standard chemotherapy for pancreatic cancer. Patients receiving this treatment had a notable improvement in overall survival, with a 26% reduction in risk of death compared to those receiving standard therapy alone. The results, presented at ASCO 2024, suggest that this combination could provide meaningful clinical benefits for patients with advanced pancreatic ductal adenocarcinoma. Further data analysis is expected by the end of 2024.

Read more →
-PPBT
May 21, 2024
PPBTPhases
▲ +6.5%on this news· ran to +32% by day 3

Purple Biotech Reports First Quarter 2024 Financial Results CM24 Phase 2 Pancreatic Cancer Interim Data Selected for Late Breaking Abstract Poster Presentation at ASCO 2024 - Interim results to be Announced

Purple Biotech Ltd. announced its first quarter financial results for 2024, highlighting key developments related to its CM24 Phase 2 study for pancreatic cancer. The company received recognition for a Late Breaking Abstract presentation at ASCO 2024, with interim data expected to demonstrate potential advancements in treatment outcomes. Additionally, Purple is progressing with its NT219 candidate in head and neck cancer. Financially, the company reported a decline in operating loss compared to the previous year, although it continues to face challenges, including its net loss.

Read more →
-PPBT
May 2, 2024
PPBTGeneral

NASDAQ/TASE: PPBT May 2024 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward -

Purple Biotech (NASDAQ/TASE: PPBT) provided a corporate presentation highlighting its focus on advancing oncology therapies with two first-in-class drug candidates, CM24 and NT219. The company anticipates significant data read-outs throughout 2024, supported by a cash balance of $15.3 million that ensures operations through the first half of 2025. Despite the optimistic outlook, the company acknowledges inherent risks in drug development, including regulatory approvals and the uncertain market response to new therapies. The presentation emphasizes the urgent medical needs in pancreatic cancer treatment and the competitive landscape.

Read more →
-PPBT
Apr 25, 2024
PPBTPhases

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting Interim data suggests reduced risk of progression or death in the CM24/n

Purple Biotech has announced that its Phase 2 study of CM24 for pancreatic cancer has been selected for a late-breaking presentation at ASCO 2024. Interim data suggests that combining CM24 with nivolumab and standard chemotherapy may lower the risk of disease progression or death compared to standard treatment alone. The study involves approximately 60 patients across multiple centers. Full data is anticipated to be released by the end of the year, showcasing the company's development in cancer therapeutics.

Read more →
-PPBT
Mar 28, 2024
PPBTConferences/Events
▲ +9.7%on this news

Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 NT219 found to suppress cancer stem cells that promote drug resistance to KRAS G12C and KRAS G12D inhibitors and solid tumor recurrence Potential

Purple Biotech has announced the upcoming presentation of data on its oncology drug NT219 at the AACR 2024 annual meeting. NT219, a dual inhibitor targeting IRS1/2 and STAT3, shows promise in suppressing cancer stem cells that contribute to drug resistance, specifically in relation to KRAS G12C and KRAS G12D inhibitors. The data also suggest the potential for NT219 to serve as a treatment for recurrent/metastatic squamous cell carcinoma and other solid tumors. The presentation will include findings from Phase 1 studies, evaluating biomarkers that may enhance treatment efficacy.

Read more →
-PPBT
Mar 14, 2024
PPBTPhases

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines t

Purple Biotech has reported preclinical proof of concept data for its tri-specific antibody platform, which includes a NK cell engager and a conditionally activated T cell engager. This innovative platform aims to enhance therapeutic effectiveness against solid tumors while minimizing off-target effects by utilizing a unique cleavable capping technology. The trial results show a synergistic anti-tumor response in models that target 5T4-expressing cancer cells, indicating potential for advanced treatments in oncology. The company's ongoing research and collaborations further position it for significant advancements in cancer therapy.

Read more →
-PPBT
Mar 6, 2024
PPBTGeneral

NASDAQ/TASE: PPBT March 2024 CORPOR A TE PRESEN T A TION Fo r war d - lo o kin g Sta t em e nt s and Safe Harbor | 2 Certain statements in this presentation that are forward - looking and not statements of historical f

Purple Biotech (NASDAQ/TASE: PPBT) announced an upcoming corporate presentation detailing forward-looking statements regarding its drug development pipeline. The company highlights its strong financial position with a cash balance of $15.3 million and anticipates multiple clinical data readouts in 2024, focusing on its innovative oncology therapies. The pipeline includes first-in-class candidates that address high unmet medical needs in cancers, with trials ongoing and anticipated data releases slated for later this year. However, the company acknowledges significant risks associated with drug development, including regulatory challenges and competition from other therapies.

Read more →
-PPBT
Mar 5, 2024
PPBTGeneral

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Purple Biotech Ltd. reported its financial results for Q4 and full-year 2023, showcasing clinical progress in its lead candidates CM24 and NT219. The company continues to advance its research in overcoming tumor immune evasion, with upcoming data from clinical trials expected in 2024. Despite a decrease in overall net loss, the company reported a reduced cash position compared to last year, although it has a runway into mid-2025.

Read more →
-PPBT
Feb 27, 2024
PPBTPhases
▼ -5.9%on this news· ran to +29% by day 3

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024 NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29

Purple Biotech presented clinical data for its Phase 1/2 study of NT219 in combination with cetuximab during the ESMO TAT Congress 2024. The findings showed that NT219 had a 29% Objective Response Rate and a 71% Disease Control Rate in patients with recurrent/metastatic head and neck cancer. The company's leadership expressed optimism over these results, highlighting the unmet medical needs for HPV negative patients. A Phase 2 study is planned to further investigate NT219's efficacy as a treatment option.

Read more →
-PPBT
Feb 12, 2024
PPBTPhases
▼ -8.5%on this news

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial NT219 recommended dose established, anti-tumor activity demonstrated

Purple Biotech has convened a Scientific Advisory Board to focus on their drug NT219, targeting recurrent/metastatic squamous cell carcinoma of the head and neck. The board provided guidance on clinical studies and acknowledged the unmet needs in treatment options for this indication. A recommended Phase 2 dose of NT219 has been established, showing promise in demonstrating anti-tumor activity. The company is preparing to advance its development program with insights from key opinion leaders in oncology.

Read more →
-PPBT
Feb 1, 2024
PPBTPhases

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Purple Biotech Ltd. announced the determination of 100mg/kg as the recommended Phase 2 dose for NT219 in combination with cetuximab for the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck. This decision is based on data from a Phase 1/2 dose escalation study, which showed dose-dependent anti-tumor activity without any reported dose-limiting toxicities. The company intends to advance to a Phase 2 Proof of Concept study and present detailed clinical results at the ESMO TAT Congress 2024. The CEO expressed optimism about NT219 becoming a standard therapy for patients unresponsive to first-line treatments.

Read more →
-PPBT
Dec 20, 2023
PPBTGeneral
▼ -9.2%on this news

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebi

Purple Biotech Ltd. has appointed Dr. Yael Margolin to its Board of Directors, bringing 35 years of experience in biotech, pharma, and venture capital. The company also announced the resignation of Mr. Fabien Sebille as Chief Business Officer. Dr. Margolin has a robust background in supporting healthtech companies and expressed optimism about Purple's pipeline of oncological drugs. The company is anticipating multiple clinical trial results in 2024, signalling a potentially transformative year ahead.

Read more →
-PPBT
Dec 14, 2023
PPBTPhases

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial This acceleration of recruitment is expected to result in earlier look at overall survival of patients

Purple Biotech Ltd. has successfully completed patient enrollment for its Phase 2 study of CM24, an immune checkpoint inhibitor aimed at treating pancreatic ductal adenocarcinoma. This trial collaborates with Bristol Myers Squibb, focusing on evaluating CM24 in combination with nivolumab and chemotherapy. Approximately 60 patients across 18 centers in the U.S., Spain, and Israel were enlisted ahead of schedule, with interim overall survival results expected in the first half of 2024, marking a potential breakthrough for treatment in an area with dire survival statistics.

Read more →
-PPBT
Nov 21, 2023
PPBTGeneral

NASDAQ/TASE: PPBT November 2023 CORPO R A TE PRESEN T A TION Fo r ward - lookin g Sta t emen t s and Saf e Harbor | 2 Certain statements in this press release that are forward - looking and not statements of historical

Purple Biotech (NASDAQ/TASE: PPBT) has released its corporate presentation for November 2023, detailing its forward-looking statements and business strategies. The company highlights its strong cash position of $15.9 million and the anticipation of multiple clinical data read-outs in 2024. PPBT is focused on advancing oncology therapies, particularly with its investigational tri-specific antibody compounds targeting cancer treatments with high unmet needs. However, the presentation also outlines numerous risks and uncertainties related to product development, market competition, and regulatory challenges.

Read more →
-PPBT
Nov 21, 2023
PPBTPhases

Purple Biotech Reports Third Quarter 2023 Financial Results Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1/2 Dose Escalation Study Patients' Enrollment in the Phase 2 Randomized CM24 Pancreatic Ca

Purple Biotech reported its financial results for Q3 2023, highlighting initial activity in its head and neck cancer treatment NT219. The enrollment for the Phase 2 CM24 pancreatic cancer trial is ahead of schedule, accelerating the timeline for interim data analysis expected in 2024. The company also extended its cash runway to the second half of 2025, ensuring financial resources for multiple clinical trials. However, operating losses and research expenditures have risen compared to the previous year.

Read more →
-PPBT
Nov 2, 2023
PPBTGeneral

Purple Biotech Fortifies NT219 Patent Protection New patent granted in China for pharmaceutical composition of NT219 expands IP protection

Purple Biotech Ltd. has received a new patent from the China National Intellectual Property Administration for the pharmaceutical composition of NT219. This patent protects the active form of NT219 throughout its manufacturing, storage, and handling processes. The company emphasizes that this development supports their strategy for global intellectual property as they prepare for further clinical trials of NT219 in treating head and neck cancer. The new patent expands their previously established protections, highlighting the large market potential in China.

Read more →
-PPBT
Oct 19, 2023
PPBTGeneral

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Purple Biotech Ltd. has announced the successful closing of its $5 million registered direct offering, which involved the issuance of 4,347,827 American Depositary Shares (ADSs) at a price of $1.15 per ADS. Additionally, the company has issued unregistered warrants as part of a concurrent private placement. The gross proceeds from this offering will primarily fund the development of its oncology therapies, including NT219, CM24, and IM1240. The offering was facilitated by H.C. Wainwright & Co. as the exclusive placement agent, and the company has also amended existing warrants to reduce their exercise price and extend their terms.

Read more →
-PPBT
Oct 17, 2023
PPBTGeneral

Purple Biotech Announces $5 Million Registered Direct Offering

Purple Biotech has announced a $5 million registered direct offering of its American Depositary Shares (ADSs) to fund the development of its oncology therapies and for general corporate purposes. The offering includes a concurrent private placement of unregistered warrants, which are immediately exercisable. Proceeds from this capital raise will support ongoing clinical studies for the company's therapeutic candidates. The ADSs are being offered under a previously declared effective registration statement with the SEC.

Read more →
-PPBT
Oct 13, 2023
PPBTGeneral

NASDAQ/TASE: PPBT October 2023 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this press release that are forward - looking and not statements of historical fact are forwa

Purple Biotech (NASDAQ/TASE: PPBT) has released its October 2023 corporate presentation, highlighting its current cash balance of $18 million and several anticipated data read-outs in the coming years. The presentation emphasizes their first-in-class clinical stage drugs and an innovative tri-specific antibody platform aimed at treating cancers with high unmet medical needs. However, it also cautions stakeholders regarding the inherent risks associated with drug development and the uncertainties in achieving regulatory approvals. The leadership team boasts a wealth of experience, which may contribute positively to the company's ongoing efforts in the pharmaceutical landscape.

Read more →
-PPBT
Oct 6, 2023
PPBTPhases

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Purple Biotech Ltd. has reported promising new biomarker data for its lead drug CM24, an anti-CEACAM1 monoclonal antibody, presented at the AACR Special Conference. The data suggest that higher levels of CEACAM1-positive tumor infiltrating lymphocytes are associated with increased survival rates in pediatric patients with advanced pancreatic cancer. CM24 is currently being evaluated in a Phase 2 study in combination with nivolumab and standard chemotherapy, with future data expected soon. The results may indicate a novel mechanism of action for CM24 in addressing tumor immune evasion.

Read more →
-PPBT
Oct 3, 2023
PPBTPhases

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab; 2 out of 4

Purple Biotech Ltd. has announced positive interim results from their Phase 1/2 study of NT219, a first-in-class dual inhibitor, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. In the highest dose cohort of NT219 combined with cetuximab, two out of four patients experienced a confirmed partial response. The drug was well tolerated, demonstrating no dose-limiting toxicities. The company plans to advance NT219 further into clinical development for this challenging cancer indication, aiming to improve treatment options for patients with limited therapies available.

Read more →
-PPBT
Sep 21, 2023
PPBTConferences/Events

Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on

Purple Biotech Ltd. will present new data on its CM24 pancreatic cancer therapy at the upcoming AACR Special Conference on September 28, 2023. The presentation will focus on Phase 1 study results, including survival rates and biomarker assessments in patients with advanced pancreatic cancer, in combination with nivolumab. Following the poster presentation, the company will provide details through a press release. Purple Biotech aims to address tumor immune evasion and drug resistance through its clinical-stage therapies.

Read more →
-PPBT
Sep 13, 2023
PPBTGeneral

NASDAQ/TASE: PPBT September 2023 CORPORATE PRESENTATION Forward - looking Statements and Safe Harbor | 2 Certain statements in this press release that are forward - looking and not statements of historical fact are for

Purple Biotech (NASDAQ/TASE: PPBT) provided a corporate presentation highlighting its forward-looking statements and future expectations. The company has a strong cash balance of $18 million and anticipates several data readouts in 2023 and 2024. Its development pipeline includes first-in-class therapies aimed at addressing significant unmet needs in oncology. However, the risks associated with regulatory approvals and complex drug development processes are also acknowledged.

Read more →
-PPBT
Aug 22, 2023
PPBTPhases

Purple Biotech Reports Second Quarter 2023 Financial Results Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 study Clinical data from both studies expe

Purple Biotech reported its financial results for the second quarter of 2023, highlighting significant progress in its clinical trials. The recruitment pace for the CM24 Phase 2 study has exceeded expectations, contributing to an extended cash runway into the first half of 2025. The company anticipates revealing important interim data from its ongoing studies in the coming months. Despite the positive developments, the report noted increases in operating and net losses compared to the previous year, primarily due to rising research and development costs.

Read more →
-PPBT
Jul 11, 2023
PPBTPhases

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients Purple's innovative immuno-oncology, chemotherapy-free regimen reports encouraging Overall Survival data in 3 rd line

Purple Biotech announced positive results from its Phase 1 dose escalation study of CM24 in patients with advanced pancreatic cancer. The study, involving 11 patients treated with a combination of CM24 and nivolumab, demonstrated encouraging overall survival rates comparable to historical chemotherapy data. Importantly, no drug limiting toxicities were reported, indicating the treatment was well tolerated. Based on the results, the company plans to proceed with a Phase 2 randomized study to further evaluate the efficacy of CM24 combined with nivolumab.

Read more →
-PPBT
May 16, 2023
PPBTGeneral

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023

Purple Biotech Ltd. reported its financial results for Q1 2023, highlighting a significant acquisition of tri-specific antibodies, which will bolster its product pipeline. The company is optimistic about its clinical programs, with important data readouts expected later in the year. Efforts are underway to identify biomarkers for better patient selection in ongoing trials. Financially, Purple Biotech has seen a decrease in research expenses, leading to improved net losses compared to the previous year.

Read more →
-PPBT
Apr 25, 2023
PPBTGeneral

Purple Biotech Debuts Scientific Advisory Board Scientific Advisory Board inaugurates new KOL support structure for Purple Biotech Three advisors bring expertise as researchers, oncologists and academicians

Purple Biotech has announced the establishment of its Scientific Advisory Board (SAB), aimed at providing strategic guidance and scientific expertise for its oncology pipeline. This new structure will include regular meetings to review clinical trials and R&D activities. The board consists of three prominent cancer researchers with extensive backgrounds in solid tumor research, which the company anticipates will lead to improved outcomes in developing novel cancer therapies. This move reflects Purple Biotech's commitment to harnessing expert insights in advancing their therapeutic missions.

Read more →
-PPBT
Apr 19, 2023
PPBTPhases

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors New preclinical data from study presented at the American Association for Cancer Research

Purple Biotech reported promising preclinical data at the AACR 2023 Annual Meeting regarding their novel small molecule NT219. This dual inhibitor shows potential in re-sensitizing resistant tumors to immune checkpoint inhibitors, enhancing anti-tumor immunity. The study suggests that NT219 can convert 'cold' tumors to 'hot' and may improve treatment outcomes for patients. Ongoing clinical studies are set to evaluate NT219 in combination with cetuximab for specific cancer types.

Read more →
-PPBT
Mar 24, 2023
PPBTGeneral

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron Board of Directors appoints Isaac Israel, Board member and former CEO, as acting CEO Company's business plan and clinical development programs continue as p

Purple Biotech Ltd. announced that CEO Gil Efron is on temporary medical leave due to hospitalization following an accident. Isaac Israel, a current Board member and former CEO, has been appointed as the acting CEO during Efron's recovery period. The company confirms that its business plan and clinical development programs will continue as planned, with no anticipated changes to its corporate progress or programs.

Read more →
-PPBT
Mar 16, 2023
PPBTPhases

Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study Reduction in neutrophil extracellular traps (NETs) markers Potential association between patient survival and CEACAM1 positive lymphocytes

Purple Biotech has reported promising results from a Phase 1 dose escalation study of its therapy CM24 combined with nivolumab in patients with advanced cancers. The data revealed significant reductions in serum myeloperoxidase, suggesting effective targeting of neutrophil extracellular traps (NETs). Additionally, there appeared to be a positive correlation between patient survival and the presence of CEACAM1 positive lymphocytes. The company plans to present further findings at an upcoming medical conference.

Read more →
-PPBT
Feb 14, 2023
PPBTPhases

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

Purple Biotech Ltd. has announced the dosing of the first patient in the randomized portion of its Phase 2 clinical trial for CM24, aimed at treating advanced metastatic pancreatic cancer. The trial will compare the efficacy of CM24 combined with nivolumab and standard chemotherapy against standard chemotherapy alone. So far, the safety run-in phase has shown no dose-limiting toxicities, and the trial is taking place at various sites across the US, Spain, and Israel. Interim results are expected in the second half of 2023, with the hope of providing new treatment options for patients with limited therapeutic alternatives.

Read more →
-PPBT
Feb 8, 2023
PPBTGeneral

Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023

Purple Biotech Ltd. reported its financial results for the fourth quarter and full-year 2022, revealing a strong balance sheet and an expanded pipeline following the acquisition of Immunorizon. The company is optimistic about the upcoming clinical data readouts from its lead programs, NT219 and CM24, which are focused on innovative cancer therapies targeting the tumor microenvironment. Despite these positives, Purple Biotech experienced increased operating losses and research expenses, highlighting ongoing financial challenges. The company plans to advance multiple clinical trials throughout 2023, aiming for significant developments in its oncology pipeline.

Read more →
-PPBT
Feb 3, 2023
PPBTGeneral

NASDAQ/TASE: PPBT February 2023 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this press release that are forward - looking and not statements of historical fact are forw

Purple Biotech (NASDAQ/TASE: PPBT) has provided a corporate presentation outlining its strong financial position with $35.7 million in cash as of September 30, 2022. The company is focused on advancing its pipeline of first-in-class cancer therapies, including clinical drugs like CM24 and NT219, with multiple data read-outs expected in 2023. The leadership team includes experienced individuals with backgrounds in well-established pharmaceutical companies. This strengthens the potential for positive outcomes in the company's ongoing and future drug development efforts.

Read more →
-PPBT
Feb 2, 2023
PPBTGeneral

Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer Immunorizon's lead compound targets 5T4 antigen and

Purple Biotech Ltd. has announced the acquisition of Immunorizon Ltd., which expands its pipeline with tri-specific antibody therapies targeting cancer. This acquisition includes a lead compound that conditionally activates T cells and natural killer cells, aimed at enhancing the immune response within the tumor microenvironment. The deal involves an upfront payment of $3.5 million in cash and shares, with additional potential milestones amounting to $94 million. This strategic move aligns with Purple Biotech's goal to develop effective treatments that can overcome tumor immune evasion.

Read more →
-PPBT
Jan 6, 2023
PPBTGeneral

NASDAQ/TASE: PPBT January 2023 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forwar

Purple Biotech (NASDAQ/TASE: PPBT) provided insights into its corporate presentation focusing on future operations and drug development. The company highlighted its robust cash reserve of $35.7 million and the advancement of two first-in-class cancer therapies, CM24 and NT219. Several clinical trial updates are anticipated in 2023, although challenges such as funding, regulatory approvals, and market reception were acknowledged as potential risks. The management team features experienced professionals from notable pharmaceutical firms.

Read more →
-PPBT
Jan 3, 2023
PPBTGeneral

Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments As a subsidiary of Clalit Healthcare Services, Israel's largest HMO, Mor Research App

Purple Biotech has announced a research collaboration with Mor Research Applications, granting it early access to oncology treatment candidates developed in Clalit Healthcare Services' 14 hospitals. This partnership aims to accelerate Purple Biotech's pipeline expansion by selecting promising assets for further development and commercialization. The CEO of Purple Biotech expressed excitement about leveraging unique assets that could lead to innovative cancer therapies. Mor Research Applications, as Clalit's technology transfer arm, is committed to advancing high-value oncology treatments.

Read more →
-PPBT
Nov 15, 2022
PPBTConferences/Events

Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis Data demonstrate suppression by CM24 of NET-promoting cancer cell migration and metastasis Findings sugge

Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis demonstrate suppression by CM24 of NET-promoting cancer cell migration and metastasis suggest potential new treatment target for metastasis REHOVOT, Israel, Nov. 15, 202

Read more →
-PPBT
Nov 9, 2022
PPBTConferences/Events

NASDAQ/TASE: PPBT November 2022 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forwa

| 1 NASDAQ/TASE: PPBT November 2022 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe ha

Read more →
-PPBT
Nov 8, 2022
PPBTGeneral

Purple Biotech Reports Third Quarter 2022 Financial Results Well capitalized with cash runway through 2024 Clinical progress for both programs, CM24 and NT219

Purple Biotech Reports Third Quarter 2022 Financial Well capitalized with cash runway through 2024 Clinical progress for both programs, CM24 and REHOVOT, Israel, November 8, 2022 -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT),

Read more →
-PPBT
Nov 2, 2022
PPBTGeneral

Purple Biotech Appoints Lior Fhima as Chief Financial Officer Seasoned financial executive strengthens management team REHOVOT, Israel, NOVEMBER 2, 2022 -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biot

Purple Biotech Appoints Lior Fhima as Chief Seasoned financial executive strengthens management REHOVOT, Israel, NOVEMBER 2, 2022 -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-cla

Read more →
-PPBT
Aug 4, 2022
PPBTGeneral

Purple Biotech Reports Second Quarter 2022 Financial Results

Purple Biotech Reports Second Quarter 2022 Financial REHOVOT, Israel, August 4, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech," or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harness

Read more →
-PPBT
Jul 14, 2022
PPBTGeneral

Purple Biotech Announces Executive Leadership Changes Gil Efron appointed as Chief Executive Officer Isaac Israel to transition to advisor role, continue as Board member

Biotech Announces Executive Leadership Changes appointed as Chief Executive Officer Israel to transition to advisor role, continue as Board member Israel, July 14, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinica

Read more →
-PPBT
Jun 6, 2022
PPBTConferences/Events

NASDAQ/TASE: PPBT June 2022 CORPORATE PRESENTATION Forward - looking Statements and Safe Harbor | 2 Certain statements in this presentation that are forward - looking and not statements of historical fact are forward -

| 1 NASDAQ/TASE: PPBT June 2022 CORPORATE PRESENTATION Forward - looking Statements and Safe Harbor | 2 Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor

Read more →
-PPBT
May 27, 2022
PPBTPhases

Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile A Confirmed Partial Response in GEJ Patient, Stable Disease demonstrated in 75% of pati

Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile Confirmed Partial Response in GEJ Patient, Stable Disease demonstrated in 75% of patients with mutated-KRAS colon cancer Israel, May 27, 2022 -- Purpl

Read more →
-PPBT
May 17, 2022
PPBTPhases

Purple Biotech Announces the Initiation of Phase 2 Study for CM24 in 2L PDAC Patients Decision based on positive interim Phase 1b data in pancreatic ductal adenocarcinoma (PDAC)

Biotech Announces the Initiation of Phase 2 Study for CM24 in 2L PDAC Patients based on positive interim Phase 1b data in pancreatic ductal adenocarcinoma (PDAC) REHOVOT, Israel, May 17, 2022 -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a cl

Read more →
-PPBT
May 12, 2022
PPBTGeneral

Purple Biotech Reports First Quarter 2022 Financial Results

Purple Biotech Reports First Quarter 2022 Financial Results REHOVOT, Israel, May 12, 2022 - Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor imm

Read more →
-PPBT
Apr 11, 2022
PPBTPhases

Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting First-in-class monoclonal antibody in combination with Opdivo (nivolumab) demons

Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting First-in-class monoclonal antibody in combination with Opdivo (nivolumab) demonstrates strong safety and an initial efficacy profile for

Read more →
-PPBT
Feb 9, 2022
PPBTGeneral

Purple Biotech Reports Second Half and Full-Year 2021 Financial Results

Biotech Reports Second Half and Full-Year 2021 Financial Results Israel, February 9, 2022 - Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immu

Read more →
-PPBT
Feb 4, 2022
PPBTGeneral

Purple Biotech Issues Letter to Shareholders

Purple Biotech Issues Letter to Shareholders REHOVOT, Israel, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor

Read more →
-PPBT
Jan 6, 2022
PPBTGeneral

Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors

Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors REHOVOT, Israel, January 6, 2022 - Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and

Read more →
-PPBT
Dec 9, 2021
PPBTGeneral

Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer

Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer REHOVOT, Israel, December 9, 2021 - Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effectiv

Read more →
-PPBT
Dec 6, 2021
PPBTPhases

Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of Multiple Cancers Supporting Potential Expansion of Clinical Program Part 2 is a Dose Escalation Study of

Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of Multiple Cancers Supporting Potential Expansion of Clinical Program Dose Escalation Study of NT219, in Combination with cetuximab (ERBITUX ), in Patients with Rec

Read more →
-PPBT
Nov 16, 2021
PPBTConferences/Events

NASDAQ/TASE: PPBT November 2021 CORPORATE PRESENTATION 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward -

NASDAQ/TASE: PPBT November 2021 CORPORATE PRESENTATION 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor p

Read more →
-PPBT
Nov 10, 2021
PPBTGeneral

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the “ Meeting ”) of Purple Biotech Ltd. (the “ Company ”) will be held o

_________________________________ NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the Meeting ) of Purple Biotech Ltd. (the Company ) will be held on Wednesday, December 22, 2021, at 4:30 p.m. Israel time a

Read more →
-PPBT
Nov 4, 2021
PPBTGeneral

Purple Biotech Ltd. Consolidated Unaudited Statements of Financial Position as of: September 30 December 31 2021 2020 USD thousands USD thousands Assets Cash and cash equivalents 9,117 11,247 Short term deposits 36,447 4

Consolidated Unaudited Statements of Financial Position as of: September 30 December 31 2021 2020 USD thousands USD thousands Assets Cash and cash equivalents 9,117 11,247 Short term deposits 36,447 46,558 Trade receivables 500 500 Other cu

Read more →
-PPBT
Oct 26, 2021
PPBTGeneral

Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219 Collaboration to Study NT219 in Combination with anti-CTLA4 and anti-PD1/PDL1 Antibodies

Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219 Collaboration to Study NT219 in Combination with anti-CTLA4 and anti-PD1/PDL1 Antibodies REHOVOT, Israel, October 26, 2021 - Purple Biotech Ltd. ("Purple Biotech", or the "Company") (N

Read more →
-PPBT
Oct 22, 2021
PPBTGeneral

Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance Research Highlights Underlying the IRS1 Phos

Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance Research Highlights Underlying the IRS1 Phosphorylation Status as a Memory Mechanism that Modulates C

Read more →
-PPBT
Sep 13, 2021
PPBTPhases

Purple Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update One Advanced Pancreatic Cancer Patient Demonstrated a P

Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update Advanced Pancreatic Cancer Patient Demonstrated a Partial Response in First Dose Cohort in Combination with Nivolumab E

Read more →
-PPBT
Aug 5, 2021
PPBTGeneral

Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results

Biotech Provides Corporate Update and Reports First Half 2021 Financial Results Israel, August 5, 2021 - Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcomi

Read more →
-PPBT
Jun 9, 2021
PPBTGeneral

Purple Biotech Ltd. Consolidated Unaudited Statements of Financial Position as of: March 31 December 31 2021 2020 USD thousands USD thousands Assets Cash and cash equivalents 10,195 11,247 Short term deposits 45,258 46,5

Consolidated Unaudited Statements of Financial Position as of: March 31 December 31 2021 2020 USD thousands USD thousands Assets Cash and cash equivalents 10,195 11,247 Short term deposits 45,258 46,558 Trade receivables 500 500 Other curre

Read more →
-PPBT
Jun 4, 2021
PPBTPhases

Purple Biotech Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Adva

Purple Biotech Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors Partial Response Observed in a Patient

Read more →
-PPBT
May 20, 2021
PPBTPhases

Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting Initial Data from Ongoing Phase 1/2 Clinical Trial of NT219 in Adults with Advanced Solid Tumors and Head and Neck Cancer to be Highl

Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting Data from Ongoing Phase 1/2 Clinical Trial of NT219 in Adults with Advanced Tumors and Head and Neck Cancer to be Highlighted REHOVOT, Israel, May 20, 2021 (GLOBE NEWSWIRE) -- Purple Biote

Read more →
-PPBT
May 19, 2021
PPBTGeneral

Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors REHOVOT, Israel, May XX, 2021 - Purple Biotech Ltd. ( Purple Biotech , or the Company ) (NASDAQ/TASE: PP

Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors REHOVOT, Israel, May XX, 2021 - Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-clas

Read more →
-PPBT
Apr 23, 2021
PPBTPhases

Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients Preliminary Data from First Part of Study Anticipated in Second Half of 2021

Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients Data from First Part of Study Anticipated in Second Half of 2021 Israel, April 23, 2021 (GLOBE NEWSWIRE) -- Purple Biotech (Nasdaq/TASE: PPBT), a clinical-stage company de

Read more →
-PPBT
Apr 13, 2021
PPBTConferences/Events

Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting

Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting TEL AVIV, Israel, April 13, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage c

Read more →
-PPBT
Mar 19, 2021
PPBTPhases

Purple Biotech Announces Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers Study Being Conducted in Clinical Collaboration with Bristol Myers Squibb Preliminary Data from First Pa

Purple Biotech Announces Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers Study Being Conducted in Clinical Collaboration with Bristol Myers Squibb Preliminary Data from First Part of Study Expected to be Available in Second Half of

Read more →
-PPBT
Mar 3, 2021
PPBTGeneral

Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors Rehovot, Israel

Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors Rehovot, Israel, March 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective, and durable th

Read more →
-PPBT
Mar 1, 2021
PPBTGeneral

Purple Biotech Provides Corporate Update and Reports Second Half and Full Year 2020 Financial Results Rehovot, Israel

Biotech Provides Corporate Update and Reports Second Half and Full Year 2020 Financial Results Rehovot, Israel, March 01, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective, and dur

Read more →
-PPBT
Jan 6, 2021
PPBTConferences/Events

NASDAQ/TASE: PPBT JANUARY 2021 CORPORATE PRESENTATION 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward -

NASDAQ/TASE: PPBT JANUARY 2021 CORPORATE PRESENTATION 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor pr

Read more →
-PPBT
Dec 10, 2020
PPBTGeneral

Kitov Announces Name Change to Purple Biotech Ltd. New Name Reflects Company's Evolution to Advancing First-in-Class Oncology Therapies

Kitov Announces Name Change to Purple New Name Reflects Company's Evolution to Advancing First-in-Class Oncology Therapies TEL AVIV, Israel, December 10, 2020 -- Purple Biotech Ltd. (the "Company") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapi

Read more →
-PPBT
Nov 12, 2020
PPBTConferences/Events

CORPORATE PRESENTATION | NOVEMBER 2020 2 FORWARD - LOOKING STATEMENTS AND SAFE HARBOR Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking stateme

1 CORPORATE PRESENTATION | NOVEMBER 2020 2 FORWARD - LOOKING STATEMENTS AND SAFE HARBOR Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of t

Read more →
-PPBT
Nov 9, 2020
PPBTPhases

Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb The new cohort will explore the

Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb The new cohort will explore the combination of CM24, Opdivo ("nivolumab") and Abraxane ("album

Read more →
-PPBT
Oct 27, 2020
PPBTGeneral

Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219 Patent covers NT219's combinations with multiple 2 nd and 3 rd generation EGFR inhibitors, including osimertinib

Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219 Patent covers NT219's combinations with multiple 2nd and 3rd generation EGFR inhibitors, including osimertinib TEL AVIV, Israel, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Kitov

Read more →
-PPBT
Oct 22, 2020
PPBTGeneral

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the " Meeting ") of Kitov Pharma Ltd. (the " Company ") will be held on Thursday

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the "Meeting") of Kitov Pharma Ltd. (the "Company") will be held on Thursday, December 3, 2020, at 4:30 p.m. Israel time at the Company's executive offices a

Read more →
-PPBT
Oct 16, 2020
PPBTConferences/Events

New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference Data Further Support Potential of NT219 to Overcome Cancer Drug Resistance

New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference Further Support Potential of NT219 to Overcome Cancer Drug Resistance Oct. 16, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-st

Read more →
-PPBT
Sep 8, 2020
PPBTPhases

Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients Top Line Results from First Part of the Study Expected in Second Half of 2021

Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients Top Line Results from First Part of the Study Expected in Second Half of 2021 TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TAS

Read more →
-PPBT
Aug 17, 2020
PPBTGeneral

The Companies Law, 5759-1999 A Company Limited By Shares Amended and Restated Articles of Association of Kitov Pharma Ltd. Israeli Public Company Number 520031238 Interpretation; General 1. In these Articles of Associati

The Companies Law, 5759-1999 A Company Limited By Shares Amended and Restated Articles of Association Israeli Public Company Number 520031238 "person" - includes a corporate body (unless otherwise stated herein); "Shareholder" - a person who is a Registered or Unregistered

Read more →
-PPBT
Aug 12, 2020
PPBTGeneral

Kitov Pharma Announces ADS Ratio Change

Kitov Pharma Announces ADS Ratio Change TEL AVIV, Israel, August 12, 2020 -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, announced today that the Company will

Read more →
-PPBT
Aug 11, 2020
PPBTGeneral

Kitov Pharma Provides Corporate Update and Reports First Half 2020 Financial Results

Kitov Pharma Provides Corporate Update and Reports First Half 2020 Financial Results TEL AVIV, Israel, August 11, 2020 -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug res

Read more →
-PPBT
Jul 8, 2020
PPBTPhases

Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients Company Evaluating NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for the Treatment o

Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients Evaluating NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for the Treatment of Recurrent and/or Metastatic Solid Tumors and Head and Neck Cancer Dat

Read more →
-PPBT
Jul 8, 2020
PPBTGeneral

Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody Patent coverage for CM24 now extends to the U.S. and the

Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody coverage for CM24 now extends to the U.S. and the EU AVIV, Israel, July 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage compan

Read more →
-PPBT
Jul 2, 2020
PPBTGeneral

PROXY STATEMENT EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS This Proxy Statement is being furnished to the holders of ordinary shares, no par value, and to holders of American Depository Shares (" ADSs "), each represe

____________________ EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS This Proxy Statement is being furnished to the holders of ordinary shares, no par value, and to holders of American Depository Shares ("ADSs"), each representing one ordinary share issued by the Bank of New Yo

Read more →
-PPBT
Jul 2, 2020
PPBTGeneral

Kitov Pharma Issues CEO Shareholder Letter Providing Business Update Emerging oncology pipeline continues to advance Strong balance sheet with over $60M in cash

Pharma Issues CEO Shareholder Letter Providing Business Update Emerging oncology pipeline continues to advance Strong balance sheet with over $60M in cash AVIV, July 02, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancin

Read more →
-PPBT
Jul 1, 2020
PPBTGeneral

NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of Shareholders (the " Meeting ") of Kitov Pharma Ltd. (the " Company ") will be held on Thursday

NOTICE OF EXTRAORDINARY GENERAL MEETING Notice is hereby given that an Extraordinary General Meeting of Shareholders (the "Meeting") of Kitov Pharma Ltd. (the "Company") will be held on Thursday, August 6, 2020, at 4:30 p.m. Israel time at the Company's executive offices at On

Read more →
-PPBT
Jun 25, 2020
PPBTGeneral

Kitov Closes $35.0 Million Registered Direct Offering TEL-AVIV, Israel

$35.0 Million Registered Direct Offering June 25, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced the closing of its previ

Read more →
-PPBT
Jun 23, 2020
PPBTGeneral

Kitov Announces $35.0 Million Registered Direct Offering TEL-AVIV, Israel

Kitov Announces $35.0 Million Registered Direct Offering Israel, June 23, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced

Read more →
-PPBT
May 22, 2020
PPBTFDA Updates

Kitov Announces U.S. FDA Acceptance of Investigational New Drug Application to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer Patients Company to Evaluate NT219 as Monotherapy Treatment of

Kitov Announces U.S. FDA Acceptance of Investigational New Drug Application to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer Patients Company to Evaluate NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab

Read more →
-PPBT
May 20, 2020
PPBTGeneral

Kitov Announces U.S. Commercial Launch of Consensi

Announces U.S. Commercial Launch of Consensi AVIV, Israel, May 20, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced the U.S

Read more →
-PPBT
May 19, 2020
PPBTPhases

Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting II Company Expects to Initiate Phase 1/2 Trial of NT-219 as Monotherapy Treatment of Advanced Solid Tumors and

Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting II Initiate Phase 1/2 Trial of NT-219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with cetuximab for Treatment of Recurrent or Metastatic Solid

Read more →
-PPBT
May 14, 2020
PPBTPhases

Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at American Society of Clinical Oncology 2020 Virtual Scientific Program Company Expects to Initiate P hase 1/2 Clinical trial, in Collaboration wit

Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at American Society of Clinical Oncology 2020 Virtual Scientific Program Company Expects to Initiate Phase 1/2 Clinical trial, in Collaboration with Bristol Myers Squibb, with CM-24 in Combination with n

Read more →
-PPBT
May 8, 2020
PPBTGeneral

Kitov Closes $10 Million Registered Direct Offering TEL-AVIV, Israel

Kitov Closes $10 Million Registered Direct May 8, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced the closing of its previ

Read more →
-PPBT
May 6, 2020
PPBTGeneral

Kitov Announces $10 million Registered Direct Offering TEL-AVIV, Israel

Kitov Announces $10 million Registered Direct Offering Israel, May 06, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced tha

Read more →
-PPBT
May 4, 2020
PPBTConferences/Events

Thank you Corporate Presentation May 2020 Forward - Looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statem

Thank you Corporate Presentation May 2020 Forward - Looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of th

Read more →
-PPBT
Apr 20, 2020
PPBTGeneral

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FRO

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDE

Read more →
-PPBT
Mar 17, 2020
PPBTGeneral

Kitov Closes $6.0 Million Public Offering TEL-AVIV

Kitov Closes $6.0 Million Public TEL-AVIV, March 17, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced the closing of its p

Read more →
-PPBT
Mar 12, 2020
PPBTGeneral

Kitov Announces Pricing of $6.0 Million Public Offering TEL-AVIV

Announces Pricing of $6.0 Million Public Offering March 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced pricing of a p

Read more →
-PPBT
Feb 24, 2020
PPBTPhases

Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers Phase 1/2 Study to Evaluate NT-219 as Monotherapy Treatment of Advanced Solid Tumors, as well as in Combination with cetuximab for Treat

Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers to Evaluate NT-219 as Monotherapy Treatment of Advanced Solid Tumors, as well as in Combination with cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head and Neck Cancer Details o

Read more →
-PPBT
Feb 11, 2020
PPBTGeneral

Kitov Pharma Provides Corporate Update and Reports Full-Year 2019 Financial Results

Pharma Provides Corporate Update and Reports Full-Year 2019 Financial Results AVIV, Israel, February 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and dr

Read more →
-PPBT
Feb 3, 2020
PPBTGeneral

Kitov Pharma Receives Issue Notification for a U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24 Patent Provides Coverage Until 2035 and Strengthens Company's IP Portfolio

Pharma Receives Issue Notification for a U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24 Provides Coverage Until 2035 and Strengthens Company's IP Portfolio AVIV, Israel, February 3, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-

Read more →
-PPBT
Jan 24, 2020
PPBTGeneral

Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors

Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors Jan. 24, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to o

Read more →
-PPBT
Jan 9, 2020
PPBTGeneral

Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer

Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug

Read more →
-PPBT
Jan 8, 2020
PPBTGeneral

Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule

Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasi

Read more →
-PPBT
Nov 19, 2019
PPBTGeneral

2019 Annual General Meeting

KITOV PHARMA LIMITED 2019 Annual General Meeting Notice is hereby given that the 2019 Annual General Meeting of Shareholders (the "Meeting" or the "Annual Meeting") of Kitov Pharma Limited ("Kitov" or the "Company") will be held at our executive offices at One Azrieli Center

Read more →
-PPBT
Nov 12, 2019
PPBTConferences/Events

KITOV PHARMA LIMITED Notice of 2019 Annual General Meeting of Shareholders Notice is hereby given that the 2019 Annual General Meeting of Shareholders (the " Meeting " or the " Annual Meeting ") of Kitov Pharma Limited (

KITOV PHARMA LIMITED Notice of 2019 Annual General Meeting of Notice is hereby given that the 2019 Annual General Meeting of Shareholders (the "Meeting" or the "Annual Meeting") of Kitov Pharma Limited ("Kitov" or the "Company") will be held at Kitov's executive offices at O

Read more →
-PPBT
Oct 18, 2019
PPBTConferences/Events

Thank you Corporate Presentation October 2019

Thank you Corporate Presentation October 2019 Forward - Looking Statements and Safe Harbor This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction . Certain statements in this presentation are forward - looking statements within

Read more →
-PPBT
Oct 11, 2019
PPBTGeneral

Kitov Pharma Announces Amended Marketing and Distribution Agreement with Coeptis and Provides Update on the Upcoming Launch of Consensi TM in the U.S In the amended agreement with Coeptis, Kitov will receive up to $99.5M

Pharma Announces Amended Marketing and Distribution Agreement with Coeptis and Provides Update on the Upcoming Launch of ConsensiTM AVIV, Israel, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class

Read more →
-PPBT
Oct 2, 2019
PPBTGeneral

Kitov Pharma Appoints Eric K. Rowinsky, M.D., as Chairman of its Board Appointment of industry leader brings broad R&D Oncology Experience to Board

Kitov Pharma Appoints Eric K. Rowinsky, M.D., as Chairman of its Board TEL AVIV, Israel, October 2, 2019 - Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today

Read more →
-PPBT
Sep 10, 2019
PPBTConferences/Events

Thank you Corporate Presentation September 2019

Thank you Corporate Presentation September 2019 Forward - Looking Statements and Kitov' s Safe Harbor Statement This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction . Certain statements in this presentation are forward - looki

Read more →
-PPBT
Sep 9, 2019
PPBTFDA Updates

Kitov Pharma Presents Newly Released Data for NT-219 in Reversing Pancreatic Cancer Drug Resistance Data validates NT-219 mechanism of action in reversing resistance to various FDA-approved treatments in pancreatic tumor

Pharma Presents Newly Released Data for NT-219 in Reversing Pancreatic Cancer Drug Resistance AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune e

Read more →
-PPBT
Sep 3, 2019
PPBTConferences/Events

Kitov Pharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference

Kitov Pharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference TEL AVIV, Israel, September 3, 2019 - Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resista

Read more →
-PPBT
Aug 29, 2019
PPBTConferences/Events

Kitov Pharma to Present New Data on NT-219 Targeting Cancer Drug Resistance at the AACR Pancreatic Cancer: Advances in Science and Clinical Care Conference

Pharma to Present New Data on NT-219 Targeting Cancer Drug Resistance at the AACR Pancreatic Cancer: Advances in Science and Clinical AVIV, Israel, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-cla

Read more →
-PPBT
Aug 16, 2019
PPBTGeneral

Kitov Pharma Announces Significant Progress in Closing of FameWave Acquisition Deal - Orbimed, Pontifax and Arkin Holdings to deposit $3.5 million investment in Kitov in escrow - Progress facilitates the advance of activ

Announces Significant Progress in Closing of FameWave Acquisition Deal Orbimed, Pontifax and Arkin Holdings to deposit $3.5 million investment in Kitov in escrow - Progress facilitates the advance of activities in development of the oncology asset CM Aug. 16, 2019 (GLOBE NEWSW

Read more →
-PPBT
Aug 14, 2019
PPBTGeneral

Administrative Enforcement Agreement Finalized between Kitov Pharma and the Israeli Securities Authority Israeli Investigation of Kitov and certain officers has been terminated

Enforcement Agreement Finalized between Kitov Pharma and the Israeli Securities Authority Investigation of Kitov and certain officers has been terminated AVIV, Israel, August 14, 2019 - Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-

Read more →
-PPBT
Aug 13, 2019
PPBTGeneral

Enforcement Arrangement Signed on _______________ Between: The Israel Securities Authority 22 Kanfei Nesharim St., Jerusalem Telephone: 02-6556555 Fax: 02-6513646 By the Chairman of the Israel Securities Authority (Herei

Between: The Israel Securities Authority 22 Kanfei Nesharim St., Jerusalem Telephone: 02-6556555 Fax: 02-6513646 By the Chairman of the Israel Securities Authority (Hereinafter: "the ISA" or "the Authority") And between: Kitov Pharma Ltd. Isaac Israel Through Adv. Dr. Zvi

Read more →
-PPBT
Aug 8, 2019
PPBTGeneral

Kitov Pharma Reports First Half 2019 Financial Results and Provides Business Update

Kitov Pharma Reports First Half 2019 Financial Results and Provides TEL AVIV, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resist

Read more →
-PPBT
Jul 12, 2019
PPBTGeneral

Kitov Receives Nasdaq Notification Regarding Minimum Bid Requirements

Kitov Receives Nasdaq Notification Regarding Minimum Bid Requirements TEL AVIV, Israel, July 12, 2019 - Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today ann

Read more →
-PPBT
Jun 27, 2019
PPBTGeneral

Kitov Successfully Completes IND-enabling Studies to advance NT219 for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancers

Successfully Completes IND-enabling Studies to advance NT219 for the Treatment of Patients with Recurrent or Metastatic Head and AVIV, Israel, June 27, 2019 - Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing first-in-class oncology

Read more →
-PPBT
May 16, 2019
PPBTGeneral

Thank you Kitov Pharma NT219 - Overcoming Cancer Drug Resistance Isaac Israel - Chief Executive Officer MIXiii - Biomed - May 16 th , 2019

Thank you Kitov Pharma NT219 - Overcoming Cancer Drug Resistance Isaac Israel - Chief Executive Officer MIXiii - Biomed - May 16 th , 2019 Forward - Looking Statements and Kitov ' s Safe Harbor Statement This presentation is not a prospectus or offer of securities for subscripti

Read more →
-PPBT
May 10, 2019
PPBTGeneral

Kitov Receives Notice of Allowance for Additional U.S. Patent Covering its Commercial Product Consensi

Receives Notice of Allowance for Additional U.S. Patent Covering its Commercial Product Consensi AVIV, Israel, May 10, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing first-in-class combination oncology the

Read more →
-PPBT
May 9, 2019
PPBTConferences/Events

Kitov to Present Clinical Development Plan for Oncology Candidate NT-219 at the 18th MIXiii-BIOMED Conference

to Present Clinical Development Plan for Oncology Candidate NT-219 at the 18th MIXiii-BIOMED Conference AVIV, Israel, May 9, 2019 - Kitov Pharma Ltd. (the "Company" or "Kitov") (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing first-in-class combination oncol

Read more →
-PPBT
May 1, 2019
PPBTGeneral

Kitov Announces Retirement of Founder and Executive Chairman Dr. Paul Waymack Dr. Waymack Will Continue to Serve as Kitov's Medical and Regulatory Advisor

Announces Retirement of Founder and Executive Chairman Dr. Paul Waymack Will Continue to Serve as Kitov's Medical and Regulatory Advisor AVIV, Israel, May 1, 2019 - Kitov Pharma Ltd. (the "Company" or "Kitov") (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing

Read more →
-PPBT
Apr 12, 2019
PPBTPhases

FameWave Announces Clinical Collaboration with Bristol Myers Squibb for the Planned Phase 1/2 Trial in Non-Small Cell Lung Cancer to Evaluate Immuno-Oncology Candidate CM-24 in Combination with Nivolumab (Opdivo )

Announces Clinical Collaboration with Bristol Myers Squibb for the Planned Phase 1/2 Trial in Non-Small Cell Lung Cancer to Evaluate Immuno-Oncology Candidate CM-24 in Combination with Nivolumab (Opdivo ) TEL AVIV, Israel, April 12, 2019 (GLOBE NEWSWIRE) -- FameWave Ltd. a pri

Read more →
-PPBT
Apr 8, 2019
PPBTGeneral

Proxy Statement - Annex A1 AMENDMENT TO STOCK PURCHASE AGREEMENT This Amendment Number 1 (the " Amendment ") to that certain Stock Purchase Agreement (the " Agreement ") previously entered into as of

AMENDMENT TO STOCK PURCHASE AGREEMENT This Amendment Number 1 (the "Amendment") to that certain Stock Purchase Agreement (the "Agreement") previously entered into as of March 14, 2019, by and among Kitov Pharma Ltd., an Israeli publicly traded corporation ("Buyer"), certain s

Read more →
-PPBT
Mar 22, 2019
PPBTGeneral

Proxy Statement Further to our Notice of Special General Meeting of Shareholders (the " Meeting " or the " Special Meeting ") of Kitov Ltd. (" Kitov " or the " Company ") to be held at our executive offices at One Azriel

to our Notice of Special General Meeting of Shareholders (the "Meeting" or the "Special Meeting") of Kitov Ltd. ("Kitov" or the "Company") to be held at our executive offices at One Azrieli Center, Round Tower, 19th Floor, Tel Aviv, Israel (the "Company Offices") on Monday, Apr

Read more →
-PPBT
Mar 14, 2019
PPBTGeneral

KITOV PHARMA LTD. Notice of Special General Meeting of Shareholders Notice is hereby given that a Special General Meeting of Shareholders (the " Meeting " or the " Special Meeting ") of Kitov Pharma Ltd. (" Kitov " or th

Notice of Special General Meeting of Shareholders Notice is hereby given that a Special General Meeting of Shareholders (the "Meeting" or the "Special Meeting") of Kitov Pharma Ltd. ("Kitov" or the "Company") will be held at Kitov's executive offices at One Azrieli Center, Ro

Read more →
-PPBT
Mar 14, 2019
PPBTGeneral

Kitov to Acquire Clinical Stage Candidate CM-24 Creating a Transformational Immuno-Oncology Company - Transaction adds immune oncology candidate to Kitov's pipeline which includes promising NT-219 cancer drug resistance

Kitov to Acquire Clinical Stage Candidate CM-24 Creating a Transformational Immuno-Oncology Company - Transaction adds immune oncology candidate to Kitov's pipeline which includes promising NT-219 cancer drug resistance prevention therapeutic candidate - Kitov to receive $3.5

Read more →
-PPBT
Feb 11, 2019
PPBTConferences/Events

Thank you CORPORATE PRESENTATION February 2019

Thank you CORPORATE PRESENTATION February 2019 Forward - Looking Statements and Kitov ' s Safe Harbor Statement This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction . Certain statements in this presentation are forward - looki

Read more →
-PPBT
Feb 7, 2019
PPBTGeneral

Kitov Pharma Reports Year End 2018 Financial Results and Provides Business Update

Pharma Reports Year End 2018 Financial Results and Provides Business Update AVIV, Israel, February 7, 2019 -- Kitov Pharma (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today reported its unaudited financial results for the year ended December 31, 2018 and provided

Read more →
-PPBT
Jan 18, 2019
PPBTGeneral

Kitov Closes $6 Million Registered Direct Offering TEL-AVIV, Israel

Million Registered Direct Offering TEL-AVIV, Israel, January 18, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today announced the closing of its previously announced registered direct offering of 3,428,572 American Depos

Read more →
-PPBT
Jan 16, 2019
PPBTGeneral

Kitov Announces Pricing of $6 Million Registered Direct Offering TEL-AVIV, Israel

Kitov Announces Pricing of $6 Million Registered Direct , Jan. 16, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors providing for

Read more →
-PPBT
Jan 15, 2019
PPBTGeneral

New Data on Kitov's NT219 Demonstrates its Unique Mechanism of Action and Anti-Cancer Effect NT219 is a first-in-class drug candidate with high affinity and selectivity to its target proteins Data show that even a short

New Data on Kitov's NT219 Demonstrates its Unique Mechanism of Action and Anti-Cancer Effect NT219 is a first-in-class drug candidate with high affinity and selectivity to its target proteins Data show that even a short exposure of cancerous cells to NT219 was sufficient to

Read more →
-PPBT
Jan 3, 2019
PPBTGeneral

Kitov Signs Marketing and Distribution Agreement for its Lead Product Consensi in the U.S. with Coeptis Pharmaceuticals - Kitov to receive $3.5M milestone payments and 40% - 60% of net profit on sales of Consensi - Coept

Signs Marketing and Distribution Agreement for its Lead Product Consensi in the U.S. with Coeptis Pharmaceuticals Kitov to receive $3.5M milestone payments and 40% - 60% of net profit on sales of Consensi Coeptis to cover all CMC, sales, and marketing expenses AVIV, Israel, Ja

Read more →
-PPBT
Nov 9, 2018
PPBTGeneral

Notice of 2018 Annual General Meeting

KITOV PHARMA LIMITED Notice of 2018 Annual General Meeting Notice is hereby given that the 2018 Annual General Meeting of Shareholders (the "Meeting" or the "Annual Meeting") of Kitov Pharma Limited ("Kitov" or the "Company") will be held at Kitov's executive offices at One

Read more →
-PPBT
Oct 11, 2018
PPBTGeneral

Kitov Appoints Gil Efron as Deputy Chief Executive Officer and Chief Financial Officer Simcha Rock to Retire as CFO and Remain on Kitov's Board of Directors

Kitov Appoints Gil Efron as Deputy Chief Executive Officer and Chief Financial Officer Simcha Rock to Retire as CFO and Remain on Kitov's TEL AVIV, Israel, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today anno

Read more →
-PPBT
Sep 26, 2018
PPBTConferences/Events

Kitov to Present Data on NT219 in Combination with Keytruda and Erbitux at AACR International Cancer Immunotherapy Conference Treatment with NT219 in combination with Keytruda or Erbitux converted non-responding tumors t

Kitov to Present Data on NT219 in Combination with Keytruda and Erbitux at AACR International Cancer Immunotherapy Conference Treatment with NT219 in combination with Keytruda or Erbitux converted non-responding tumors to responders TEL AVIV, Israel, Sept. 26, 2018 (GLOBE NEW

Read more →
-PPBT
Sep 18, 2018
PPBTGeneral

Kitov Pharma Updates on Motions in USA Initiated by Kitov Chairman Tel Aviv, Israel

Pharma Updates on Motions in USA Initiated by Kitov Chairman Aviv, Israel, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced that, following a filing by Kitov's Chairman of the Board and Chief Medi

Read more →
-PPBT
Sep 17, 2018
PPBTGeneral

Kitov Pharma Ltd. Condensed Consolidated Unaudited Interim Financial Statements As of

Interim Financial Statements Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2018 Page Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2018 Condensed Consolidated Interim Statements of Financial Position 2 Condensed C

Read more →
-PPBT
Aug 29, 2018
PPBTGeneral

Kitov Pharma Provides Corporate Update and Reports First Half 2018 Financial Results Tel Aviv, Israel

Pharma Provides Corporate Update and Reports First Half 2018 Financial Results Tel Aviv, Israel, August 29, 2018 - Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today provided a corporate update and reported financial results for the six month

Read more →
-PPBT
Jul 30, 2018
PPBTGeneral

Kitov Announces Settlement of Shareholder Class Action Litigation Tel Aviv, Israel

Announces Settlement of Shareholder Class Action Litigation Aviv, Israel - July 30, 2018 -- Kitov Pharma Ltd. (Nasdaq: KTOV; TASE: KTOV.TA), an innovative biopharmaceutical company, today announced that it has entered into a Stipulation of Settlement with respect to the shareho

Read more →
-PPBT
Jun 27, 2018
PPBTConferences/Events

Kitov to Host Business Update Conference Call on Monday, July 2 Tel Aviv, Israel

to Host Business Update Conference Call on Monday, July 2 Aviv, Israel - June 27, 2018 -- Kitov Pharma Ltd. (Nasdaq: KTOV; TASE: KTOV), an innovative biopharmaceutical company, today announced that it will host a business update conference call on Monday July 2nd at 8:30 am Eas

Read more →
-PPBT
Jun 15, 2018
PPBTPhases

Kitov Announces Positive Pre-Clinical Data from NT219 Demonstrating its Dose-Dependent Anti-Tumor Efficacy Results in PDX model of pancreatic cancer supports planned IND for NT219 Completes acquisition of substantially a

Announces Positive Pre-Clinical Data from NT219 its Dose-Dependent Anti-Tumor Efficacy in PDX model of pancreatic cancer supports planned IND for NT219 acquisition of substantially all minority shares of TyrNovo, June 15, 2018 AVIV, Israel, June 15, 2018 (GLOBE NEWSWIRE) -- K

Read more →
-PPBT
Jun 1, 2018
PPBTGeneral

Kitov Announces Pricing of $8,150,000 Registered Direct Offering TEL-AVIV, Israel

Announces Pricing of $8,150,000 Registered Direct Offering Israel, June 01, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors provi

Read more →
-PPBT
May 31, 2018
PPBTFDA Updates

FDA Approves Kitov's Consensi for Treatment of Osteoarthritis Pain and Hypertension New drug choice for millions of Americans offers one pill for treatment of osteoarthritis pain with a built-in antihypertensive

Approves Kitov's Consensi for Treatment of Osteoarthritis Pain and Hypertension for millions of Americans offers one pill for treatment of osteoarthritis pain with a built-in antihypertensive TEL AVIV, Israel, May 31, 2018 / GlobeNewswire/ Kitov Pharma Ltd. (NASDAQ: KTOV; TASE

Read more →
-PPBT
May 11, 2018
PPBTFDA Updates

Kitov Announces Consensi Commercialization Agreement for China Kitov to receive milestone payments of up to $9.5 million, as well as potential double-digit royalties Consensi PDUFA date of

Announces Consensi Commercialization Agreement for China to receive milestone payments of up to $9.5 million, as well as potential double-digit royalties PDUFA date of May 31, 2018, Upcoming AVIV, Israel, May 11, 2018 / GlobeNewsWire/ -- Pharma Ltd. (NASDAQ: KTOV; TASE: KTOV)

Read more →
-PPBT
Apr 13, 2018
PPBTConferences/Events

TyrNovo to Present at 2018 Annual Meeting of the American Association for Cancer Research Treatment with TyrNovo's NT219 in combination with targeted cancer drugs, as well as chemotherapy and immuno-oncology therapies, p

TyrNovo to Present at 2018 Annual Meeting of the American Association Treatment with TyrNovo's NT219 in combination with targeted cancer drugs, as well as chemotherapy and immuno-oncology therapies, prevented acquired resistance and reversed of colon, lung and head-and-neck

Read more →
-PPBT
Mar 8, 2018
PPBTConferences/Events

TyrNovo to Present at BIO-Europe Spring 2018 Conference Treatment with TyrNovo's NT219 in combination with targeted cancer drugs, as well as chemotherapy and immuno-oncology therapies, prevented acquired resistance and r

to Present at BIO-Europe Spring 2018 Conference with TyrNovo's NT219 in combination with targeted cancer drugs, as well as chemotherapy and immuno-oncology therapies, prevented acquired resistance and reversed resistance of colon, lung and head-and-neck cancers in patient-deriv

Read more →
-PPBT
Mar 5, 2018
PPBTGeneral

Kitov Pharmaceuticals Publishes Annual Report for 2017 and Issues CEO Letter to Shareholders Tel Aviv, Israel

Pharmaceuticals Publishes Annual Report for 2017 and Issues CEO Letter to Shareholders Aviv, Israel, March 5, 2018 - Kitov Pharmaceuticals (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, announced today that it filed its Annual Report for 2017 on Form 20-F

Read more →
-PPBT
Jan 29, 2018
PPBTGeneral

Unofficial English Translation from Hebrew] Corporations Authority Registrar of Companies and Partnership [Official Seal] State of Israel Ministry of Justice - Corporations Authority Registrar of Companies and Partnershi

English Translation from Hebrew] OF NAME CHANGE OF A COMPANY its name and henceforth shall be called in Jerusalem on the day of: Companies and Partnerships by: Nizam Zaml, Adv.

Read more →
-PPBT
Dec 14, 2017
PPBTGeneral

Kitov Announces Consensi as Brand Name for KIT-302

Announces Consensi as Brand Name for KIT-302 Israel, December 14, 2017 /PRNewswire/ -- Kitov Pharmaceuticals (NASDAQ: KTOV) (TASE: KTOV), an innovative biopharmaceutical company, announced today that the U.S. Food & Drug Administration (FDA) has granted permission to Kitov to

Read more →
-PPBT
Nov 29, 2017
PPBTConferences/Events

Thank you Innovative Biopharmaceuticals CORPORATE PRESENTATION November 2017

Thank you Innovative Biopharmaceuticals CORPORATE PRESENTATION November 2017 Forward - Looking Statements and Kitov's Safe Harbor Statement This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction . Certain statements in this pres

Read more →
-PPBT
Nov 1, 2017
PPBTFDA Updates

Kitov Pharmaceuticals Announces Receipt of FDA's Favorable Response to NT219's pre-IND Meeting Package TyrNovo to Initiate Clinical Development on Advanced Pancreatic Cancer Patients Long-term Strategy to Develop NT219 f

Pharmaceuticals Announces Receipt of FDA's Favorable Response to NT219's pre-IND Meeting Package to Initiate Clinical Development on Advanced Pancreatic Cancer Patients Strategy to Develop NT219 for Treatment of Additional Cancers via Collaboration with Pharmaceutical Compani

Read more →
-PPBT
Oct 26, 2017
PPBTPhases

Kitov Pharmaceuticals Announces Phase III/IV Clinical Trial for KIT-302 Successfully Meets Primary Endpoint, and also Demonstrates Drug Candidate Improves Renal Function Results Validate Primary Efficacy Endpoint Achieve

Kitov Pharmaceuticals Announces Phase III/IV Clinical Trial for KIT-302 Successfully Meets Primary Endpoint, and also Demonstrates Drug Candidate Improves Renal Function Results Validate Primary Efficacy Endpoint Achieved in Previous Successfully Completed Phase III Clinical

Read more →
-PPBT
Oct 6, 2017
PPBTGeneral

Kitov Boosts Ownership in TyrNovo and Oncology Platform Through Exchange of Shares for Stock Kitov acquires an additional 27% ownership stake in TyrNovo and NT219, its oncology therapeutic candidate, in exchange for Kito

Boosts Ownership in TyrNovo and Oncology Platform Through Exchange of Shares for Stock AVIV, Israel, October 6, 2017 /PRNewswire/ -- Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), ("Kitov" or "the Company") an innovative biopharmaceutical company, announced today th

Read more →
-PPBT
Oct 2, 2017
PPBTFDA Updates

Kitov Announces Filing by FDA of New Drug Application for KIT-302

Announces Filing by FDA of New Drug Application for KIT-302 AVIV, Israel, October 2, 2017 /PRNewswire/ -- Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) filed t

Read more →
-PPBT
Sep 28, 2017
PPBTGeneral

Kitov Pharmaceuticals Holdings Ltd. (the " Company ") In accordance with Section 318(b) of the Israeli Companies Law, 1999, and Regulation 3(b) of the Israeli Companies Regulations (Merger), 2000, the Company hereby noti

Kitov Pharmaceuticals Holdings Ltd. In accordance with Section 318(b) of the Israeli Companies Law, 1999, and Regulation 3(b) of the Israeli Companies Regulations (Merger), 2000, the Company hereby notifies its creditors that on September 28, 2017, the Company has filed with t

Read more →
-PPBT
Aug 16, 2017
PPBTGeneral

Kitov Pharmaceuticals Holdings Ltd. Condensed Consolidated Interim Financial Statements As of

Pharmaceuticals Holdings Ltd. Financial Statements Pharmaceuticals Holdings Ltd. Consolidated Interim Financial Statements as of June 30, 2017 (unaudited) Page Condensed Consolidated Interim Financial Statements as of June 30, 2017 Condensed Consolidated Interim Statements

Read more →
-PPBT
Jul 31, 2017
PPBTFDA Updates

Kitov Submits New Drug Application to FDA for KIT-302

Drug Application to FDA for KIT-302 TEL AVIV, Israel, July 31, 2017 /PRNewswire/ Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Dr

Read more →
-PPBT
Jul 18, 2017
PPBTGeneral

Kitov Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda in Immune-Oncology Preclinical Model

Kitov Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda in Immune-Oncology Preclinical Model AVIV, Israel, July 18, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announc

Read more →
-PPBT
Jul 11, 2017
PPBTGeneral

Kitov Pharmaceuticals Announces Pricing of $3.5 Million Registered Direct Offering TEL-AVIV, Israel

Pharmaceuticals Announces Pricing of $3.5 Million Registered Direct Offering TEL-AVIV, Israel July 11, 2017 -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced that it has entered into de

Read more →
-PPBT
Jun 26, 2017
PPBTFDA Updates

Kitov Updates on KIT-302 New Drug Application Anticipated PDUFA Date with FDA for Approval of Marketing on Schedule

on KIT-302 New Drug Application PDUFA Date with FDA for Approval of Marketing on Schedule TEL AVIV, Israel, June 26, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, announced today that it has begu

Read more →
-PPBT
Jun 15, 2017
PPBTConferences/Events

Thank you CORPORATE PRESENTATION June 2017

Thank you CORPORATE PRESENTATION June 2017 Forward Looking Statements and Kitov's Safe Harbor Statement This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction . Certain statements in this presentation are forward - looking state

Read more →
-PPBT
Jun 12, 2017
PPBTGeneral

Kitov Pharmaceuticals Ltd. Unaudited Pro Forma Condensed Consolidated Statement of Financial Position As of

Pharmaceuticals Ltd. Pro Forma Condensed Consolidated Statement of Financial Position of December 31, 2016 Kitov Pharmaceuticals Holdings Ltd . TyrNovo Ltd. Pro Forma adjustment (1) Kitov Pharmaceuticals Holdings Ltd. Pro forma USD thousand USD thousand USD thou

Read more →
-PPBT
Jun 8, 2017
PPBTGeneral

is hereby given that a Special General Meeting of Shareholders (the "Meeting" or the "Special Meeting")

Special General Meeting is hereby given that a Special General Meeting of Shareholders (the "Meeting" or the "Special Meeting") of Kitov Pharmaceuticals Holdings Limited ("Kitov" or the "Company") will be held at our executive offices at One Azrieli Center, Round Tower, 23rd F

Read more →
-PPBT
Jun 1, 2017
PPBTGeneral

PHARMACEUTICALS HOLDINGS LIMITED

PHARMACEUTICALS HOLDINGS LIMITED of 2017 Special General Meeting of Shareholders is hereby given that a Special General Meeting of Shareholders (the "Meeting" or the "Special Meeting") of Kitov Pharmaceuticals Holdings Limited ("Kitov" or the "Company") will be held at Kitov's

Read more →
-PPBT
Apr 3, 2017
PPBTGeneral

U.S. Food and Drug Administration Grants Kitov a Waiver for New Drug Application Filing Fee

Administration Grants Kitov a Waiver for New Drug Application AVIV, Israel, April 3, 2017 /PRNewswire/ -- Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has gr

Read more →
-PPBT
Mar 27, 2017
PPBTGeneral

Management's Discussion and Analysis of Financial Condition and Results of Operations as of

Management's Discussion and Analysis of Financial Condition and Results of Operations as of December 31, 2016, and for the calendar year then ended Results for the Year Ended December 31, 2016 and development expenses for the year ended December 31, 2016 were $4.2 million, an

Read more →
-PPBT
Mar 8, 2017
PPBTGeneral

Kitov Announces License Agreement for KIT-302 in South Korea Definitive agreement grants Kuhnil Pharmaceutical Co. Ltd. an exclusive license to manufacture and market KIT-302 in South Korea Transaction is Kitov's First L

Announces License Agreement for KIT-302 in South Korea agreement grants Kuhnil Pharmaceutical Co. Ltd. an exclusive license to manufacture and market KIT-302 in South Korea is Kitov's First License Agreement for KIT-302 is the leading NSAID product in South Korea with reported

Read more →
-PPBT
Feb 10, 2017
PPBTGeneral

Kitov Announces Settlement Agreement with Minority Shareholder of Recently Acquired TyrNovo Minority shareholder will invest additional funds to support TyrNovo's R&D in concert with Kitov's investment Tel Aviv, Israel

Announces Settlement Agreement with Minority Shareholder of Recently Acquired TyrNovo Minority shareholder will invest additional funds to support TyrNovo's R&D in concert with Kitov's investment Tel Aviv, Israel -- February 10, 2017 -- Kitov Pharmaceuticals Holdings Ltd. (NA

Read more →
-PPBT
Feb 9, 2017
PPBTGeneral

Unofficial English Translation [TASE Logo] Tel-Aviv Stock Exchange

To: To the attention of: Members of TASE Ltd. Head of Securities Department To Whom It May Concern, Security: Kitov Pharmaceuticals Holdings Ltd. (Security No.: 765016) Number Index Original Factor Close of Trading Factor 1 TA- all share 1 0 2 TA - Growth 1

Read more →
-PPBT
Feb 1, 2017
PPBTFDA Updates

Kitov Granted Notice of Allowance from U.S. Patent & Trademark Office for KIT-302 Patent Further Strengthens Company's IP position ahead of Planned New Drug Application to be Submitted to FDA Tel Aviv, Israel

Kitov Granted Notice of Allowance from U.S. Patent & Trademark Office for KIT-302 Patent Further Strengthens Company's IP position ahead of Planned New Drug Application to be Submitted to FDA Tel Aviv, Israel -- February 1, 2017 -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ

Read more →
-PPBT
Jan 23, 2017
PPBTGeneral

Thank you Streamlined Innovative Drug Development TyrNovo's NT 219 A New Concept in Cancer Therapy January 23 , 2017 2017 Proprietary and Confidential Forward Looking Statements and Kitov's Safe Harbor Statement This pre

Thank you Streamlined Innovative Drug Development TyrNovo's NT 219 A New Concept in Cancer Therapy January 23 , 2017 2017 Proprietary and Confidential Forward Looking Statements and Kitov's Safe Harbor Statement This presentation is not a prospectus or offer of securities for su

Read more →
-PPBT
Jan 17, 2017
PPBTGeneral

Kitov to Host Business Update Call on Monday

to Host Business Update Call on Monday, January 23, 2017 to Discuss Acquisition of Oncology Company, TyrNovo, Ltd. Development On Track For An NDA Submission to the FDA in Q1 2017 Aviv, Israel -- January 17, 2017 -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV; TASE: KTOV

Read more →
-PPBT
Jan 12, 2017
PPBTConferences/Events

Kitov Enters Immuno-Oncology Field Through Acquisition of TyrNovo - TyrNovo's NT219 drug candidate works by overcoming tumors' cancer drug resistance and would be developed as a combination drug, presenting a new paradig

Kitov Enters Immuno-Oncology Field Through Acquisition of TyrNovo TEL AVIV, Israel, January 12, 2017 /PRNewswire/ - Kitov Pharmaceuticals Holdings Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, announced today the expansion of its pipeline through the acqu

Read more →
-PPBT
Dec 7, 2016
PPBTFDA Updates

Kitov Successfully Completes All KIT-302 Testing Required for New Drug Application to U.S. FDA - KIT-302 successfully completed 6 months stability testing required for the submission of a New Drug Application - NDA to be

Successfully Completes All KIT-302 Testing Required for New Drug Application to U.S. FDA - KIT-302 successfully completed 6 months stability testing required for the submission of a New Drug Application - NDA to be Filed during Q1 2017 AVIV, Israel, December 7, 2016 /PRNewswi

Read more →
-PPBT
Dec 6, 2016
PPBTGeneral

The Companies Law, 5759-1999 A Company Limited By Shares Amended and Restated Articles of Association of Kitov Pharmaceuticals Holdings Ltd. Israeli Public Company Number 520031238 Interpretation; General 1. In these Art

The Companies Law, 5759-1999 A Company Limited By Shares Amended and Restated Articles of Association Kitov Pharmaceuticals Holdings Ltd. Israeli Public Company Number 520031238 "person" - includes a corporate body (unless otherwise stated herein); "Shareholder" - a person w

Read more →
-PPBT
Oct 27, 2016
PPBTConferences/Events

KITOV PHARMACEUTICALS HOLDINGS LIMITED Notice of 2016 Annual General Meeting of Shareholders Notice is hereby given that the 2016 Annual General Meeting of Shareholders (the " Meeting " or the " Annual Meeting ") of Kito

PHARMACEUTICALS HOLDINGS LIMITED of 2016 Annual General Meeting of Shareholders given that the 2016 Annual General Meeting of Shareholders (the "Meeting" or the "Annual Meeting") of Kitov Pharmaceuticals Holdings Limited ("Kitov" or the "Company") will be held at Kitov's exec

Read more →
-PPBT
Sep 27, 2016
PPBTGeneral

Kitov Reports successful results for additional KIT-302 pharmacokinetic bioequivalence study KIT-302 Successfully Meets U.S. Food and Drug Administration Bioequivalence Standards for 2.5 mg Amlodipine Dose Tel Aviv, Isra

Reports successful results for additional KIT-302 pharmacokinetic bioequivalence study Successfully Meets U.S. Food and Drug Administration Bioequivalence Standards for 2.5 mg Amlodipine Dose Aviv, Israel, September 27, 2016 - Kitov Pharmaceuticals Holdings Ltd. (NASDAQ/TASE:

Read more →
-PPBT
Sep 7, 2016
PPBTConferences/Events

Company Presentation September 2016 2016 Kitov Pharmaceuticals Holdings Ltd. Kitov Pharmaceuticals Streamlined Late - Stage Drug Development Forward Looking Statements and Kitov's Safe Harbor Statement This presentation

Company Presentation September 2016 2016 Kitov Pharmaceuticals Holdings Ltd. Kitov Pharmaceuticals Streamlined Late - Stage Drug Development Forward Looking Statements and Kitov's Safe Harbor Statement This presentation is not a prospectus or offer of securities for subscription

Read more →
-PPBT
Sep 6, 2016
PPBTPhases

Pharmaceuticals to PRESENT DATA from

Pharmaceuticals to PRESENT DATA from a U.S. Market ASSESSMENT for KIT-302 TO BE MADE ON SEPTEMBER 12, 2016 AT THE 18TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE IN NEW YORK CITY Aviv, Israel, September 6, 2016 - Kitov Pharmaceuticals Holdings Ltd. (NASDAQ/TASE: KTO

Read more →
-PPBT
Aug 17, 2016
PPBTGeneral

Pharmaceuticals Holdings Ltd.

Pharmaceuticals Holdings Ltd. Financial Statements Pharmaceuticals Holdings Ltd. Consolidated Interim Financial Statements as of June 30, 2016 Page Condensed Consolidated Interim Financial Statements as of June 30, 2016 Condensed Consolidated Interim Statements of Financial

Read more →
-PPBT
Aug 10, 2016
PPBTFDA Updates

Kitov Announces Issuance of U.S. Patent Securing Long-Term Exclusivity for KIT-302 Ahead of New Drug Application to the FDA TEL-AVIV, Israel

Announces Issuance of U.S. Patent Long-Term Exclusivity for KIT-302 Ahead of New Drug Application to the FDA Israel August 10, 2016 -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced tha

Read more →
-PPBT
Jul 5, 2016
PPBTGeneral

Kitov Pharmaceuticals Announces Closing of a $12 Million Follow-On Public Offering in the U.S.A. TEL-AVIV, Israel

Kitov Pharmaceuticals Announces Closing of a $12 Million Follow-On Public Offering in the U.S.A. TEL-AVIV, Israel July 5, 2016 -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced the clos

Read more →
-PPBT
Jun 29, 2016
PPBTGeneral

Kitov Pharmaceuticals Announces Pricing of $12 Million Follow-On Public Offering in the U.S.A. TEL-AVIV, Israel

Kitov Pharmaceuticals Announces Pricing of $12 Million Follow-On Public Offering in the U.S.A. TEL-AVIV, Israel June 29, 2016 -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced pricing f

Read more →
-PPBT
Jun 28, 2016
PPBTFDA Updates

Kitov's Lead Drug KIT-302 Achieves Manufacturing Milestone Ahead of Planned NDA Filing with U.S. FDA - Study conducted by Dexcel Pharma demonstrated initial stability - Kitov on track to file New Drug Application for KIT

Kitov's Lead Drug KIT-302 Achieves Manufacturing Milestone Ahead of Planned NDA Filing with U.S. FDA TEL-AVIV, Israel (PR Newswire) June 28, 2016 -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, anno

Read more →
-PPBT
Jun 24, 2016
PPBTPhases

Kitov Reports New Data Demonstrating KIT-302 Has Beneficial Effects on Kidney Function - Findings address a major concern of kidney injury side effects caused by current standard of care drugs - Patients in Phase III tri

Kitov Reports New Data Demonstrating KIT-302 Has Beneficial Effects on Kidney Function TEL-AVIV, Israel (PR Newswire) June 24, 2016 -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced ne

Read more →
-PPBT
May 27, 2016
PPBTFDA Updates

Kitov Announces Completion of Manufacturing Pivotal Batches of KIT-302 Required for Registration in the U.S. Company plans to file New Drug Application with U.S. FDA at the end of 2016 TEL-AVIV, Israel (PR Newswire)

Kitov Announces Completion of Manufacturing Pivotal Batches of KIT-302 Required for Registration in the U.S. Company plans to file New Drug Application with U.S. FDA at the end of 2016 TEL-AVIV, Israel (PR Newswire) May 27, 2016 -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV),

Read more →
-PPBT
May 24, 2016
PPBTGeneral

KITOV PHARMACEUTICALS HOLDINGS LIMITED __________________ Special General Meeting of Shareholders

KITOV PHARMACEUTICALS Special General Meeting Notice is hereby given that a Special General Meeting of Shareholders (the "Meeting" or the "Special Meeting") of Kitov Pharmaceuticals Holdings Limited ("Kitov" or the "Company") will be held at Kitov's executive offices at One

Read more →
-PPBT
May 20, 2016
PPBTGeneral

KITOV PHARMACEUTICALS HOLDINGS LIMITED Notice of Special General Meeting of Shareholders Notice is hereby given that a Special General Meeting of Shareholders (the " Meeting " or the " Special Meeting ") of Kitov Pharmac

PHARMACEUTICALS HOLDINGS LIMITED of Special General Meeting of Shareholders given that a Special General Meeting of Shareholders (the "Meeting" or the "Special Meeting") of Kitov Pharmaceuticals Holdings Limited ("Kitov" or the "Company") will be held at Kitov's executive off

Read more →
-PPBT
May 12, 2016
PPBTFDA Updates

Kitov Receives Pre-NDA Meeting Response From FDA for KIT-302, Supporting its NDA Submission Kitov expects to submit New Drug Application to FDA at the end of 2016 for KIT-302 - a fixed dose combination that simultaneousl

Kitov Receives Pre-NDA Meeting FDA for KIT-302, Supporting its NDA Submission expects to submit New Drug Application to FDA at the end of 2016 for KIT-302 - a fixed dose combination that simultaneously treats osteoarthritis pain and hypertension Tel-Aviv, Israel (PR Newswire

Read more →
-PPBT
May 10, 2016
PPBTFDA Updates

Kitov Reports KIT-302 Study Successfully Meets U.S. Food & Drug Administration Bioequivalence Standards Kitov plans to file New Drug Application with FDA this year for combination drug that simultaneously treats osteoart

Kitov Reports KIT-302 Study Successfully Meets U.S. Food & Drug Administration Bioequivalence Standards plans to file New Drug Application with FDA this year for combination drug that simultaneously treats osteoarthritis pain and May 10, 2016 - Kitov Pharmaceuticals (NASDAQ/TA

Read more →
-PPBT
May 5, 2016
PPBTConferences/Events

Kitov Pharmaceuticals to Present at Pioneers 2016, Presented by Joseph Gunnar, in NYC on

Pharmaceuticals to Present at Pioneers 2016, Presented by Joseph Gunnar, in NYC on May 5, 2016 AVIV, Israel, May 4, 2016 /(GLOBE NEWSWIRE)/ -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), a late-stage drug development company, today announced that Dr. J. Paul Waymack, Kitov's Ch

Read more →
-PPBT
Mar 3, 2016
PPBTFDA Updates

Amendment of the Articles 145. Unless provided otherwise herein, and specifically in Article 9, and Articles 83 through Article 87, any amendment of these Articles shall require the approval of an ordinary majority, in p

The Companies Law, 5759-1999 A Company Limited By Shares Amended and Restated Articles of Association Kitov Pharmaceuticals Israeli Public Company Number 520031238 "person" - includes a corporate body (unless otherwise stated herein); "Shareholder" - a person who is a Regist

Read more →
-PPBT
Jan 25, 2016
PPBTGeneral

2015 Annual General Meeting

KITOV PHARMACEUTICALS 2015 Annual General Meeting It has been more than two years since the listing of Kitov on the Tel Aviv Stock Exchange, and I would like to reach out to you and update you on the status of the Company at this time and as to the Company's plans for the fut

Read more →
-PPBT
Jan 11, 2016
PPBTConferences/Events

Kitov Pharmaceuticals to Present at Biotech Showcase in San Francisco on

Pharmaceuticals to Present at Biotech Showcase in San Francisco on January 11, 2016 Israel, January 11, 2016 /PRNewswire/ -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), a late-stage drug development company, today announced that Dr. J. Paul Waymack, Kitov's Chairman of the Boar

Read more →
-PPBT
Jan 8, 2016
PPBTGeneral

Kitov Pharmaceuticals Appoints Dr. Gil Ben-Menachem as V.P. of Business Development - Seasoned pharma exec previously at managerial and business development roles at Teva Pharmaceuticals and Dexcel Pharma - Company plans

Pharmaceuticals Appoints Dr. Gil Ben-Menachem as V.P. of Business Development AVIV, Israel, January 08, 2016 -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), a late-stage drug development company, today announced that it has appointed Dr. Gil Ben-Menachem as Vice President Busine

Read more →
-PPBT
Dec 17, 2015
PPBTGeneral

Summary Translation into English of Staff Position of the Israel Securities Authority [Israel Securities Authority Letterhead]

Translation into English of Staff Position of the Israel Securities Authority Authority Letterhead] Subject: Change to reporting in accordance with Chapter E'3 of the Securities Law On November 26, 2015 the Company announced the completion of an initial public offering of it

Read more →
-PPBT
Dec 17, 2015
PPBTPhases

Kitov Pharmaceuticals Reports Additional Data from its Phase III Trial on the Beneficial Blood Pressure Effects of KIT-302 - KIT-302 could address a major safety concern in the use of pain medication for the healthcare c

Kitov Pharmaceuticals Reports Additional Data from its Phase III Trial on the Beneficial Blood Pressure Effects of KIT-302 TEL AVIV, Israel, Dec. 17, 2015 -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug developme

Read more →
-PPBT
Dec 11, 2015
PPBTGeneral

Kitov Pharmaceuticals Holdings Ltd. (the "Company") Notice of a Special General Meeting of the holders of options of the Company not traded on the Tel Aviv Stock Exchange Dear Securities Holder: Please take notice that t

Kitov Pharmaceuticals Holdings Ltd. (the "Company") a Special General Meeting of the holders of options of the Company on the Tel Aviv Stock Exchange Dear Securities Holder: that the Company hereby announces that a special general meeting of the holders of options and warran

Read more →
-PPBT
Dec 10, 2015
PPBTPhases

Kitov Pharmaceuticals to Announce Interim Results of the Pivotal Phase III Trial on

Kitov Pharmaceuticals to Announce Interim Results of the Pivotal Phase III Trial on December 15, 2015 at 7:00am ET Company to hold press conference in Tel Aviv at 2:00 pm local time Tel Aviv, Israel, December 10, 2015 - Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) (TAS

Read more →
-PPBT
Dec 6, 2015
PPBTGeneral

Kitov Pharmaceuticals Holdings Ltd. (the "Company")

Kitov Pharmaceuticals Holdings Ltd. (the "Company") Israel Securities Authorities Tel Aviv Stock Exchange Ltd. calling of a Special General Meeting of the shareholders of the Company announces that a special general meeting of the shareholders of the Company shall be convene

Read more →
-PPBT
Dec 1, 2015
PPBTConferences/Events

Company Presentation December 2015 2015 Kitov pharmaceuticals Ltd.

Company Presentation December 2015 2015 Kitov pharmaceuticals Ltd. Kitov Pharmaceuticals Streamlined Late - Stage Drug Development Kitov Pharmaceuticals Streamlined Late - Stage Drug Development This presentation is not a prospectus or offer of securities for subscription or sal

Read more →
-PPBT
Nov 25, 2015
PPBTGeneral

Kitov Pharmaceuticals Holdings Announces Closing of U.S. Initial Public Offering Tel Aviv, Israel

Kitov Pharmaceuticals Holdings Announces Closing of U.S. Initial Public Offering Aviv, Israel, November 25, 2015 - Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) (TASE: KTOV), a biopharmaceutical company focused on the development of therapeutic candidates for the simulta

Read more →
-PPBT
Nov 20, 2015
PPBTGeneral

Kitov Pharmaceuticals Holdings Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing Tel Aviv, Israel

Kitov Pharmaceuticals Holdings Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing Israel, November 20, 2015 - Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV), a biopharmaceutical company focused on the development of therapeutic candidates for the simulta

Read more →
Competitive Position
How PPBT ranks across every disease it competes in
Competitive Position is a premium feature
See how PPBT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial